Comparative effectiveness of exercise, antidepressants and their combination in treating non-severe depression: a systematic review and network meta-analysis of randomised controlled trials

Francesco Recchia,1 Chit K Leung,1 Edwin C Chin,1 Daniel Y Fong,2 David Montero,1 Calvin P Cheng,3 Suk Yu Yau,4 Parco M Siu1

ABSTRACT

Objective To assess the comparative effectiveness of exercise, antidepressants and their combination for alleviating depressive symptoms in adults with non-severe depression.

Design Systematic review and network meta-analysis.

Data sources Embase, MEDLINE, PsyClinQ, Cochrane Library, Web of Science, Scopus and SportDiscus.

Eligibility criteria Randomised controlled trials (1990–present) that examined the effectiveness of an exercise, antidepressant or combination intervention against either treatment alone or a control/placebo condition in adults with non-severe depression.

Study selection and analysis Risk of bias, indirectness and the overall confidence in the network were assessed by two independent investigators. A frequentist network meta-analysis was performed to examine postintervention differences in depressive symptom severity between groups. Intervention drop-out was assessed as a measure of treatment acceptability.

Results Twenty-one randomised controlled trials (n=2551) with 25 comparisons were included in the network. There were no differences in treatment effectiveness among the three main interventions (exercise vs antidepressants: standardised mean differences, SMD, −0.12; 95% CI −0.33 to 0.10, combination versus exercise: SMD, 0.00; 95% CI −0.33 to 0.33, combination vs antidepressants: SMD, −0.12; 95% CI −0.40 to 0.16), although all treatments were more beneficial than controls. Exercise interventions had higher drop-out rates than antidepressant interventions (risk ratio 1.31; 95% CI 1.09 to 1.57). Heterogeneity in the network was moderate (τ²=0.03; I²=46%).

Conclusions The results suggest no difference between exercise and pharmacological interventions in reducing depressive symptoms in adults with non-severe depression. These findings support the adoption of exercise as an alternative or adjuvant treatment for non-severe depression in adults.

Systematic review registration PROSPERO CRD4202122656.

WHAT ARE THE FINDINGS?

⇒ Exercise alleviates symptoms of depression to a similar extent as antidepressant treatments alone or in combination with exercise.

⇒ The drop-out rates of exercise studies was higher than that of antidepressant studies.

HOW MIGHT IT IMPACT ON CLINICAL PRACTICE IN THE FUTURE?

⇒ These results suggest that exercise may be used as an alternative treatment approach for the management of non-severe depression in adults.

⇒ This study adds to the body of evidence for the benefits of exercise in managing depression and will inform future mental health treatment guidelines regarding the protective role of exercise for non-severe depression.

INTRODUCTION

Depression is a leading cause of disability worldwide and is estimated to affect over 320 million people.2 It is a disabling condition that affects the quality of life,3 is estimated to cost society over US$920 billion due to lost productivity alone.3 Depression has a lifetime prevalence of up to 19% and is highly associated with the onset of other somatic and psychiatric disorders.4 5

Currently, second-generation antidepressant medications are one of the first-line treatments for depression.6 However, the evidence on their effectiveness remains controversial because the immediate and short-term benefits may be small and the long-term balance between benefit and harm is poorly understood.7 Individual-level meta-analyses have found a direct relationship between the magnitude of depressive symptoms and the effectiveness of antidepressants.8–10 Thus, the benefits of antidepressants in non-severe depression have been argued to be minimal.11 This is concerning considering that most patients with depression report symptoms below the threshold for severe depression.12 13 In addition, high costs, fear of addiction and possible adverse effects limit the applicability of antidepressants in some real-life settings.14 Reluctance to use antidepressants may also be found in patients with non-severe symptoms due to low perceived need or effectiveness of the medication and/or social stigmatisation.15 Although there is evidence that antidepressants have some beneficial effects on milder forms of depression compared with placebo,16 concerns over the risk-to-benefit ratio and the availability of alternative treatments...
raise questions about the appropriateness of pharmacological treatments for non-severe depression.

Recently, lifestyle interventional strategies incorporating diet, sleep and physical activity have been recognised as protective treatments for depression.\(^\text{17,18}\) Specifically, the use of exercise as an alternative treatment for non-severe depression is endorsed by several treatment guidelines (EPA in Europe, CANMAT in Canada, NICE in the UK and RANZCP in Australia).\(^\text{19-22}\) In contrast, the clinical practice guidelines provided by the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) support exercise therapy only when antidepressants or psychotherapy treatments are ineffective or unacceptable.\(^\text{23}\) Moreover, the DSM-5 guidelines state that there is a lack of evidence to recommend exercise as an official treatment. This contradicts the report by the European Psychiatric Association that states that there is sufficient data supporting exercise for the management of mild-to-moderate depression.\(^\text{19}\) The contrasting statements conveyed by international treatment guidelines preclude drawing definitive conclusions regarding the role of exercise as a treatment for non-severe depression.

Comparing the effects of exercise and antidepressants is essential to elucidate whether exercise is a suitable non-pharmacological treatment approach to manage non-severe depression, and to inform current international treatment guidelines about the protective role of exercise in depression. We therefore conducted a systematic review and network meta-analysis to determine the comparative effectiveness of exercise and antidepressants on depressive symptoms in adults with non-severe depression. In addition, we examined the effect of combination treatment versus either treatment alone to explore the potential synergistic action of exercise and antidepressants. We also set to compare the drop-out rates of participants among interventions as a measure of treatment acceptance.

METHODS
This review was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension guidelines for network meta-analyses\(^\text{23}\) and was registered in PROSPERO (identifier CRD42021226561).

Search strategy and selection criteria
We searched seven electronic databases (Embase, MEDLINE (PubMed), PsycINFO, Cochrane Library, Web of Science, Scopus and SportDiscus) from January 1990 to January 2022 for relevant articles published in any language. A detailed description of the search strategy is provided in online supplemental appendix 1. We handsearched references of previous meta-analyses and articles of interest to identify further eligible studies. Two independent researchers performed the search using pre-established criteria. In case of disagreement, a third author was consulted, and the disagreement was resolved by consensus.

We included randomised controlled trials investigating the effect of (1) exercise versus antidepressants, (2) either exercise or antidepressants versus a control condition and (3) exercise combined with antidepressants versus either treatment alone, during an initial treatment attempt in adults with non-severe depression. Non-severe depression was defined as a diagnosis of major depressive disorder with mild-to-moderate symptoms. We included studies that recruited participants with a clinical diagnosis of depression assessed using standard diagnostic criteria and determined to have mild-to-moderate symptoms using a psychiatric interview or the cut-off score of a validated rating scale. If studies did not specify the severity of depression for recruitment, they were included if (1) mild symptoms were reported as minimum inclusion criteria and (2) mean baseline depression scores were of moderate severity or lower.

We defined exercise according to the American College of Sports Medicine guideline as ‘planned, structured and repetitive bodily movement aimed to improve and/or maintain one or more components of physical fitness’.\(^\text{24}\) Studies were excluded if they involved mind-body practices such as yoga or Tai Chi, as these comprise a number of behavioural techniques that might confound the effect of physical exercise. Studies on antidepressants were included if they assessed the effectiveness of a second-generation antidepressant that was approved by the Food and Drug Administration (FDA) and that was administered in doses within the standard therapeutic range.\(^\text{25}\) To ensure homogeneity among participant and trial characteristics, studies where all participants had treatment-resistant depression or a primary comorbidity, as well as studies where exercise or antidepressants were added to another treatment (eg, psychotherapy), were excluded. Studies with the intervention lasting less than 4 weeks were also excluded.

Outcomes
The primary outcome was depressive symptoms severity, defined as the score on a depression scale at the primary endpoint. When multiple scales were used, we applied a hierarchical protocol based on the most frequently employed scale. The secondary outcome was treatment acceptability, defined as the number of participants who withdrew from the study before the end of the intervention. We used overall drop-out as a measure of acceptability, as this encompasses all possible reasons for discontinuation, including tolerance and satisfaction to the intervention.

Data extraction
Two authors independently extracted sample sizes, post-intervention mean scores of depressive symptoms, SD and number of drop-outs in each study. Disagreements were resolved by consensus. When SD were missing, we calculated them using previously validated methods.\(^\text{26,27}\) If SD could not be computed from the available data and the authors were unreachable, these were imputed. Sensitivity analyses were performed for studies where SD were imputed. If dichotomous data for the number of drop-outs was not clearly reported, we computed the drop-outs based on the difference between participants randomised at baseline and those who completed the intervention. If data were missing, the authors were directly contacted to request additional information. If the authors were unresponsive or unreachable the study was excluded.

We extracted information on participants (ie, mean age, sex and baseline symptoms severity) and trial characteristics (ie, first author, publication date, type of intervention, type of control, outcome assessment and intervention duration) using a data extraction form embedded in an Excel spreadsheet.

We assessed risk of bias using the Cochrane risk of bias assessment tool (RoB-2).\(^\text{28}\) We used the Confidence in Network Meta-Analysis (CINeMA) model to assess the confidence of the entire network.\(^\text{29}\) Additional information regarding RoB-2 and CINeMA can be found in online supplemental appendix 2.

Data analysis
We conducted a network meta-analysis with a frequentist framework using the netmeta package in the statistical software R (V.4.0.3). We designed a network including (1) exercise, (2) antidepressants and (3) exercise plus antidepressants as direct
comparisons. If studies included control interventions, these were grouped together and added as a further comparison. We performed random effects pairwise meta-analyses with the Hartung-Knapp-Sidik-Jonkman method\(^{30}\) for direct comparisons to estimate standardised mean differences (SMD) from continuous outcomes and risk ratios (RR) from dichotomous outcomes. Indirect evidence was assessed using the whole network. The random effects netmeta model was used to control for the effect of multiam trials.

Results from the primary outcome (depressive symptoms severity) were expressed as SMD, and results from the secondary outcome (acceptability) were expressed as RR. The 95% CI were provided whenever possible.

We used the Cochran’s Q statistic to determine the pairwise between-study heterogeneity. In addition, \(I^2\) was calculated to determine the level of variance between studies. We used \(I^2\) to evaluate the percentage of variance caused by between-study heterogeneity. It was assumed that heterogeneity was common across the entire network. We assessed the transitivity in the network by a visual inspection of study characteristics: mode participant age (≥60 or <60), mode proportion of women (≥50% or <50%), mean intervention duration and mode depression scale used.\(^{31,32}\) We performed meta-regression analyses within comparisons to assess the potential influence of the study characteristics on the effect sizes.\(^{33}\) We measured inconsistency in the network with local and global approaches using netsplit and decomp_design functions, respectively. The former was used to assess inconsistency between direct and indirect evidence within each comparison; the latter was used to assess inconsistency between comparisons. We presumed that every participant fitting our eligibility criteria could potentially be randomised to any of the treatments compared. We used the P-score proposed by Rücker and Schwarzer to rank the treatments within the network.\(^{33}\)

Owing to an insufficient number of studies in each comparison group, subgroup and meta-regression analyses, as well as the assessment of publication bias, could not be performed to explore potential sources of heterogeneity across the network. Sensitivity analyses were performed by excluding studies with high indirectness and risk of bias, studies with participants older than 60, studies with interventions longer than 12 weeks and studies that used an attention/active or passive control comparison.\(^{31}\)

**RESULTS**

The literature search identified 23,209 potential studies. After exclusion of studies by title and abstract, 329 full-text records were screened and 21 were included in the main analysis (online supplemental material efigure 1). All studies were written in English.

**Study characteristics**

Overall, 2,551 participants in 25 pairwise comparisons were assigned to one of the three treatments and control groups (figure 1). The comparison studies included: antidepressants versus controls (n=11), exercise versus controls (n=6), combined treatments versus antidepressants (n=4) and combined treatments versus exercise (n=1). Three studies provided direct evidence on the comparative effects of antidepressants and exercise. Control interventions included placebo (n=11), attention control (n=2), stretching (n=2), no intervention (n=1) and wait-list (n=1). We visually assessed the distribution of study characteristics across direct comparisons (table 1, online supplemental material etable 1). Participant age, the proportion of women and the outcome measure used were balanced across comparisons. The duration of the intervention differed among comparisons, with the exercise versus antidepressants comparison having the mean longest intervention (19 weeks), and the antidepressants versus control comparison having the shortest (9 weeks). Nonetheless, meta-regression analyses suggest that none of the study characteristics influenced the treatment effect (online supplemental material etable 2). Overall, we considered the assumption of transitivity to be valid.

Risk of bias was determined to be low in 5 studies, moderate in 15 studies and high in 1 study (online supplemental material etable 3). Most of the network evidence relied on moderate risk of bias and low-moderate indirectness (online supplemental material efigure 2, 3 and online supplemental material etable 4). The confidence in the network was moderate-to-high for all comparisons of interest (online supplemental material etable 5).

**Depressive symptoms severity**

At the end of the interventions, exercise (SMD, −0.45; 95% CI −0.67 to −0.23), antidepressants (SMD, −0.33; 95% CI −0.48 to −0.19) and combined treatments (SMD, −0.45; 95% CI −0.76 to −0.14) were superior in reducing depressive symptoms compared with controls (table 2). There were no differences among the main treatments. Exercise had a similar beneficial effect to that of antidepressants (SMD, −0.12; 95% CI −0.33 to 0.10), and the effect of combined treatments was similar to the effect of exercise (SMD, 0.00; 95% CI −0.33 to 0.33) and antidepressants (SMD, −0.12; 95% CI −0.40 to 0.16) alone. The ranking of treatments based on the P-score is reported in online supplemental material etable 6.

The network meta-analysis showed that there was moderate heterogeneity (\(t^2=0.03\); \(I^2=46.2\%\)), which was mostly caused by the comparison of exercise versus control (\(Q=15.80\); df=4; \(p=0.003\)). All other comparisons showed no evidence of heterogeneity. Inconsistency was assessed both within and between comparisons. There was no evidence of inconsistency within any of the comparisons of interest (online supplemental material etable 7). Similarly, no inconsistency between comparisons was observed (\(Q=5.62\), df=5, \(p=0.34\)).

The pairwise meta-analysis supported the findings of the network meta-analysis, with both exercise (SMD, −0.58; 95% CI −1.14 to −0.01) and antidepressants (SMD, −0.33;
Table 1: Characteristics of the included studies

<table>
<thead>
<tr>
<th>Study</th>
<th>Mean age (SD)</th>
<th>Gender (M/F)</th>
<th>Baseline score (SD)</th>
<th>Depression scale</th>
<th>Intervention</th>
<th>Duration (weeks)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bjerkenstedt, 2005*</td>
<td>50 (12)</td>
<td>23M 86F</td>
<td>24.5 (4)</td>
<td>HAM-D</td>
<td>Fluoxetine Placebo</td>
<td>4</td>
</tr>
<tr>
<td>Blumenthal et al. 1999†</td>
<td>57 (7)</td>
<td>43M 113F</td>
<td>17.9 (7.2)</td>
<td>HAM-D</td>
<td>Exercise Sertraline Aerobic exercise + sertraline</td>
<td>16</td>
</tr>
<tr>
<td>Blumenthal et al. 2007* ‡</td>
<td>52 (8)</td>
<td>35M 114F</td>
<td>17 (4)</td>
<td>HAM-D</td>
<td>Exercise Sertraline Placebo</td>
<td>16</td>
</tr>
<tr>
<td>Danielsson, 2014*</td>
<td>46 (14)</td>
<td>10M 32F</td>
<td>24 (4.6)</td>
<td>MADRS</td>
<td>Exercise + antidepressants Antidepressants + advice</td>
<td>10</td>
</tr>
<tr>
<td>Detke, 2002*</td>
<td>41 (14)</td>
<td>83M 184F</td>
<td>20.4 (3.4)</td>
<td>HAM-D</td>
<td>Duloxetine Placebo</td>
<td>9</td>
</tr>
<tr>
<td>Detke, 2004*</td>
<td>45 (12)</td>
<td>47M 139F</td>
<td>20.1 (3.5)</td>
<td>HAM-D</td>
<td>Duloxetine Placebo</td>
<td>8</td>
</tr>
<tr>
<td>Dunn, 2005¶</td>
<td>34 (7)</td>
<td>9M 21F</td>
<td>19.8 (2.1)</td>
<td>HAM-D</td>
<td>Exercise Stretching</td>
<td>12</td>
</tr>
<tr>
<td>Fava, 2005*</td>
<td>37 (11)</td>
<td>37M 53F</td>
<td>19.7 (3.2)</td>
<td>HAM-D</td>
<td>Fluoxetine Placebo</td>
<td>12</td>
</tr>
<tr>
<td>Gastpar, 2006*</td>
<td>49 (12)</td>
<td>80M 177F</td>
<td>21.9 (1.2)</td>
<td>HAM-D</td>
<td>Citalopram Placebo</td>
<td>6</td>
</tr>
<tr>
<td>Goldstein, 2004*</td>
<td>41 (13)</td>
<td>67M 113F</td>
<td>17.6 (4.9)</td>
<td>HAM-D</td>
<td>Duloxetine Placebo</td>
<td>8</td>
</tr>
<tr>
<td>Hemat-Er, 2012¶</td>
<td>18–25</td>
<td>20F</td>
<td>24.4 (5)</td>
<td>BDI</td>
<td>Exercise No-treatment</td>
<td>8</td>
</tr>
<tr>
<td>Hidalgo et al. 2021†</td>
<td>&gt; 65</td>
<td>67M 246F</td>
<td>15.5 (4.3)</td>
<td>MADRS</td>
<td>Exercise Antidepressants</td>
<td>24</td>
</tr>
<tr>
<td>Krogh, 2012¶</td>
<td>42 (11)</td>
<td>38M 77F</td>
<td>18.9 (4.4)</td>
<td>HAM-D</td>
<td>Exercise Stretching</td>
<td>12</td>
</tr>
<tr>
<td>Mao, 2015*</td>
<td>44 (15)</td>
<td>19M 18F</td>
<td>15 (3)</td>
<td>HAM-D</td>
<td>Sertraline Placebo</td>
<td>12</td>
</tr>
<tr>
<td>Matson, 2002†</td>
<td>65 (NA)</td>
<td>27M 59F</td>
<td>17.2 (6.5)</td>
<td>HAM-D</td>
<td>Exercise + antidepressants Antidepressants + attention control</td>
<td>10</td>
</tr>
<tr>
<td>McNeil, 1991¶</td>
<td>41 (11)</td>
<td>8M 38F</td>
<td>16.1 (4.8)</td>
<td>HAM-D</td>
<td>Exercise Placebo</td>
<td>8</td>
</tr>
<tr>
<td>Moreno, 2006*</td>
<td>45 (11)</td>
<td>60 142F</td>
<td>21 (4.1)</td>
<td>HAM-D</td>
<td>Fluoxetine Placebo</td>
<td>8</td>
</tr>
<tr>
<td>Philipp, 1999*</td>
<td>46 (12)</td>
<td>40M 117F</td>
<td>22.5 (4.1)</td>
<td>HAM-D</td>
<td>Imipramine Placebo</td>
<td>8</td>
</tr>
<tr>
<td>Sadeghi, 2016¶</td>
<td>21 (1)</td>
<td>24M 6F</td>
<td>22.9 (4.2)</td>
<td>BDI-II</td>
<td>Exercise Attention control</td>
<td>8</td>
</tr>
<tr>
<td>Siqueira, 2016¶</td>
<td>39 (11)</td>
<td>16M 41F</td>
<td>19.8 (3.1)</td>
<td>HAM-D</td>
<td>Exercise + sertraline Sertraline</td>
<td>4</td>
</tr>
</tbody>
</table>

*Included in the antidepressants versus control pairwise comparison.
†Included in the exercise versus control pairwise comparison.
‡Included in the exercise plus antidepressants versus antidepressants comparison.
§Included in the exercise plus antidepressants versus exercise comparison.
¶Included in the exercise plus control pairwise comparison.
BDI, Beck Depression Inventory; HAM-D, Hamilton Depression Rating Scale; MADRS, Montgomery-Asberg Depression Rating Scale; NA, not applicable.

Table 2: Results on the comparative effectiveness of the interventions from the network and pairwise meta-analyses

<table>
<thead>
<tr>
<th>Combination</th>
<th>Study</th>
<th>Mean age (SD)</th>
<th>Gender (M/F)</th>
<th>Baseline score (SD)</th>
<th>Depression scale</th>
<th>Intervention</th>
<th>Duration (weeks)</th>
</tr>
</thead>
<tbody>
<tr>
<td>-0.00 (-0.33 to 0.33)</td>
<td>-0.13 (-0.63 to 0.36)</td>
<td>-0.58 (-1.14 to -0.01)</td>
<td>NA*&lt;sup&gt;†&lt;/sup&gt;</td>
<td>Exercise</td>
<td>Placebo</td>
<td>4</td>
<td></td>
</tr>
<tr>
<td>-0.12 (-0.40 to 0.16)</td>
<td>-0.58 (-1.14 to -0.01)</td>
<td>NA*&lt;sup&gt;‡&lt;/sup&gt;</td>
<td>Exercise</td>
<td>Placebo</td>
<td>4</td>
<td></td>
<td></td>
</tr>
<tr>
<td>-0.45 (-0.76 to -0.14)</td>
<td>-0.33 (-0.49 to -0.16)</td>
<td>NA*&lt;sup&gt;‡&lt;/sup&gt;</td>
<td>Antidepressants</td>
<td>Control</td>
<td>4</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Results of the network meta-analyses are presented in grey and results of the pairwise meta-analyses are presented in white. Estimates are displayed as column versus row for the network meta-analyses and row versus column for the pairwise meta-analyses. Results are expressed as standardised mean differences (SMD). A negative SMD indicates a superiority of the first treatment over the comparison treatment.

*No evidence on I² is available as there was only one study for that comparison.
†No studies compared combination treatment versus no treatment.
‡No studies compared combination treatment versus antidepressants.
N, number of studies in the comparison; NA, not available.

95%CI −0.49 to −0.16) showing greater improvements over the controls. The comparison of exercise and antidepressants showed no evidence of the superiority of one treatment over the other (SMD, −0.08; 95%CI −0.29 to 0.12). Similarly, there was no evidence of the superiority of combined treatments over exercise (SMD, 0.18; 95%CI −0.20 to 0.55) and antidepressants (SMD, −0.13; 95%CI −0.63 to 0.36) alone (online supplemental appendix 3).

Acceptability

Four studies were excluded from the secondary outcome analyses as they failed to report the drop-out rate in the intervention groups and data could not be extracted from the text oracceptability.

there were no drop-outs in any of the interventions of interest. Drop-out rates in the exercise group were greater than in the antidepressant group (RR 1.31; 95% CI 1.09 to 1.57) and control group (RR 1.29, 95% CI 1.03 to 1.61) across all studies (table 3). No other differences were observed among the interventions.

The pairwise meta-analyses were in line with the results of the network analysis, as the drop-out rates were higher in the exercise group than in the antidepressant group (RR 1.40; 95%CI 1.13 to 1.72). There was no evidence of heterogeneity among pairwise comparisons (table 3, online supplemental eappendix 3).

**DISCUSSION**

This is the first network meta-analysis to comparatively assess the effectiveness of exercise, antidepressants and combined treatments on depressive symptoms in adults with non-severe depression. Results showed that all treatments had similar beneficial effects on depressive symptoms when compared with the controls, but no treatment was superior to another. Assessment of acceptability showed that antidepressant treatments induced fewer intervention drop-outs than exercise.

Our findings align with the recommendations provided by European, Canadian, Australian and UK treatment guidelines supporting the use of exercise as an alternative treatment for non-severe depression. Results showed that all treatments had similar beneficial effects on depressive symptoms when compared with the controls, but no treatment was superior to another. Assessment of acceptability showed that antidepressant treatments induced fewer intervention drop-outs than exercise.

Combination treatment did not demonstrate greater beneficial effects on depressive symptoms compared with either treatment alone, probably due to the limited number of studies included in our analyses. The effects of the combination of exercise and pharmacotherapy on depression remains largely unclear. Although some studies have attempted to explain the possible synergism between the two interventions, evidence of their combined effectiveness against pharmacological treatment alone is still inconclusive.

Our findings do not support the synergistic effects of exercise and antidepressants; however, considering the various health benefits of physical exercise, using exercise as an adjunctive treatment to pharmacotherapy may counterbalance the side effects that are often associated with antidepressant use and promote a faster recovery.

Exercise interventions induced greater drop-outs than antidepressant treatments, although only one study reported a substantial difference in drop-out rates between the two interventions. In this study, 58% and 40% of participants withdrew from the exercise and antidepressant groups, respectively. This is considerably higher than what reported in the two other trials directly comparing exercise and antidepressants, where drop-out rates ranged from 14% to 26%. Despite the greater drop-out rates in the exercise group, the proportion of participants with adverse events was greater in the antidepressant group, with 22% reporting adverse events compared with 9% in the exercise group. In our study, we used overall drop-out as a measure of treatment acceptability. It is possible that an analysis of drop-out due to adverse events alone would have led to different results. Clearly, both interventions have limitations in securing treatment adherence. Exercise is physically demanding and harder to implement in comparison to standard pharmacological treatments. On the other hand, antidepressant treatments are associated with greater adverse effects, higher costs and social stigma. Although both interventions can effectively alleviate depressive symptoms, different strategies must be adopted to enhance treatment adherence in depressed individuals. Further research is needed to address this topic, possibly differentiating between treatment satisfaction, adverse events and overall study withdrawal.

In the current review, evidence from studies that compared exercise and/or antidepressants to each other or to a control comparison was gathered. To our own surprise, only 6 and 11 studies comparing exercise and antidepressants to control were found, respectively. Several exercise studies were excluded because they did not include participants with a clinical diagnosis of depression, or because some but not all of participants randomised were taking antidepressants, thereby confounding the true effect of exercise. Most of the antidepressant studies were excluded because participants reported levels of depression that are indicative of moderate-to-severe depression. This was also reflected in a comprehensive network meta-analysis by Cipriani et al., who analysed over 500 antidepressant studies and found that 89% only recruited participants with moderate-to-severe symptoms (mean Hamilton Rating Scale score of 25.7). Compared with Cipriani et al., our study had tighter inclusion criteria to ensure that the transitivity assumption was not violated. This led to the exclusion of several antidepressant studies in mild-to-moderate depression. Overall, there is an imbalance between the proportion of studies assessing treatment effectiveness in mild-to-moderate depression and those focusing on severe depression. This imbalance has been suggested to be partly caused by the inclusion criteria used for FDA-funded trials, where higher cut-off scores are imposed at baseline to increase the sensitivity of the antidepressant versus placebo comparison. We hope that the current study will contribute to highlight the clinical importance of non-severe depression, and that more clinical trials on non-severe depression can be conducted in the future.

**Limitations**

There were some limitations in this study. First, the overall low number of studies available for each comparison precluded us to explore potential sources of heterogeneity and publication bias,
and may have generated inaccurate estimates of between-study heterogeneity. This limited the interpretation of our findings, which need to be corroborated by further research. Second, the control groups in all comparisons were combined into a single node. While all antidepressant studies used a placebo comparison, exercise studies used various types of control. This might have contributed to the heterogeneity detected in the exercise-control comparison. Although our sensitivity analyses found no considerable changes in study effects after excluding studies with an active or passive control comparison, the effect of exercise might have been overestimated and needs to be validated by additional high-quality studies. Similarly, we combined exercise, antidepressant and combination treatments into their respective nodes without accounting for differences within interventions. This method was chosen because previous network meta-analyses showed little heterogeneity among antidepressant\(^6\) and exercise\(^9\) interventions. Yet, antidepressant studies can vary by type, dose and duration of antidepressant used, whereas exercise studies can vary by type, frequency, intensity and duration of the training sessions. These differences might have affected the overall heterogeneity of the network. Third, this study examined the comparative effectiveness of exercise and antidepressants in mild-to-moderate depression, but did not explore the potential benefits of exercise in individuals with more severe symptoms. This limited the interpretation of our findings, which cannot be extended to all depressed patients.

**CONCLUSION**

The meta-analytical evidence gathered through direct and indirect comparisons found no differences in treatment effectiveness between exercise, antidepressants and their combination. These findings support the use of exercise interventions as an alternative treatment option for non-severe depression. Results were corroborated through stringent sensitivity analyses that accounted for the quality of studies as well as types of participants and interventions. Further trials directly comparing the individual and synergistic action of exercise and antidepressants are warranted to corroborate the findings of this study.

**Correction notice**

This article has been corrected since it published Online First. The footnotes in tables 2 and 3 have been amended.

**Contributors**

All authors had full access to the data in the study and agreed to the decision to submit for publication. FR, CL and PS accessed and verified the data in this study. FR, CL and EC conducted the database search and data extraction. FR, DM and CPWC conducted the data analysis. All authors interpreted the data and wrote and edited the manuscript.

**Funding**

This work was supported by Health and Medical Research Fund (17182461) of Food and Health Bureau, Hong Kong SAR Government and the Seed Fund for Basic Research of The University of Hong Kong.

**Competing interests**

None declared.

**Patient and public involvement**

Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.

**Patient consent for publication**

Not applicable.

**Provenance and peer review**

Not commissioned; externally peer reviewed.

**Supplemental material**

This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

**Open access**

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

---

**ORCID ID**

Parco M Siu http://orcid.org/0000-0002-3548-5058

**REFERENCES**


Downloaded from http://bjsm.bmj.com on October 2022 by guest. Protected by copyright.


Comparative effectiveness of exercise, antidepressants, and their combination in treating non-severe depression: A systematic review and network meta-analysis of randomized controlled trials

Supplementary Online Content

eFigure 1. PRISMA flow chart

eFigure 2. Risk of bias contributions

eFigure 3. Indirectness contributions

eTable 1. Distribution of study characteristics

eTable 2. Meta-regression for direct comparisons

eTable 3. Risk of bias for all studies

eTable 4. Indirectness for all studies

eTable 5. Confidence in Network Meta-analysis (CINeMA) final report

eTable 6. Treatment ranking based on the P-score

eTable 7. Assessment of inconsistency within comparisons

eTable 8. Sensitivity analyses

eAppendix 1. Search strategy

eAppendix 2. Additional methodology information

eAppendix 3. Pairwise meta-analyses

eAppendix 4. References
eFigure 1. PRISMA flow chart

Records identified from:
- PubMed (n = 5,911)
- PsycInfo (n = 3,572)
- Embase (n = 13,493)
- Cochrane Library (n = 5,880)
- Scopus (n = 12,288)
- SportDiscus (n = 35)
- Web of Science (n = 4,858)

Records excluded (n = 22,880)
- Duplicate records removed (n = 22,828)
- Relevant systematic reviews and meta-analyses (n = 126)

Records screened (n = 23,209)

Reports excluded (n = 0)

Reports screened (n = 23,209)

Reports excluded:
- Ineligible population (n = 202)
- Ineligible or no comparison (n = 33)
- Ineligible study design (n = 24)
- Ineligible outcome (n = 13)
- Abstract only (n = 12)
- Secondary publication (n = 29)

Reports assessed for eligibility (n = 329)

Reports excluded:
- Ineligible population (n = 202)
- Ineligible or no comparison (n = 33)
- Ineligible outcome (n = 13)
- Abstract only (n = 12)
- Secondary publication (n = 29)

Records excluded (n = 0)

Reports assessed for eligibility (n = 56)

Reports excluded:
- Ineligible population (n = 31)
- Ineligible intervention (n = 9)
- Ineligible study design (n = 7)
- Ineligible or no comparison (n = 4)

Reports included in meta-analysis (n = 21)
eFigure 2. Risk of bias contributions
**eFigure 3. Indirectness contributions**

![Bar chart showing indirectness contributions for various conditions](chart_image)
**eTable 1. Distribution of study characteristics**

<table>
<thead>
<tr>
<th>Comparison</th>
<th>N studies</th>
<th>Participant age (years)</th>
<th>Sex (% women)</th>
<th>Intervention duration (weeks)</th>
<th>Outcome measure</th>
</tr>
</thead>
<tbody>
<tr>
<td>EX:AD</td>
<td>3</td>
<td>&lt; 60</td>
<td>≥ 50%</td>
<td>19</td>
<td>HAM-D</td>
</tr>
<tr>
<td>AD:CT</td>
<td>11</td>
<td>&lt; 60</td>
<td>≥ 50%</td>
<td>9</td>
<td>HAM-D</td>
</tr>
<tr>
<td>EX:CT</td>
<td>6</td>
<td>&lt; 60</td>
<td>≥ 50%</td>
<td>10</td>
<td>HAM-D</td>
</tr>
<tr>
<td>EX+AD:AD</td>
<td>4</td>
<td>&lt; 60</td>
<td>≥ 50%</td>
<td>11</td>
<td>HAM-D</td>
</tr>
<tr>
<td>EX+AD:EX</td>
<td>1</td>
<td>&lt; 60</td>
<td>≥ 50%</td>
<td>16</td>
<td>HAM-D</td>
</tr>
</tbody>
</table>
### eTable 2. Meta-regression for direct comparisons

<table>
<thead>
<tr>
<th>Comparison</th>
<th>N</th>
<th>Coefficient [95% CI]</th>
<th>SE</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>EX:AD</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>- Mean age</td>
<td>3</td>
<td>-0.00 [-0.16 to 0.16]</td>
<td>0.01</td>
<td>0.94</td>
</tr>
<tr>
<td>- Mean duration</td>
<td>-0.01 [-0.21 to 0.20]</td>
<td>0.02</td>
<td>0.75</td>
<td></td>
</tr>
<tr>
<td>- Proportion of women</td>
<td>-0.02 [-0.39 to 0.36]</td>
<td>0.03</td>
<td>0.67</td>
<td></td>
</tr>
<tr>
<td>- Outcome measure</td>
<td>-0.05 [-1.68 to 1.58]</td>
<td>0.13</td>
<td>0.75</td>
<td></td>
</tr>
<tr>
<td>AD:CT</td>
<td>11</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>- Mean age</td>
<td>0.01 [-0.03 to 0.05]</td>
<td>0.02</td>
<td>0.70</td>
<td></td>
</tr>
<tr>
<td>- Mean duration</td>
<td>0.02 [-0.03 to 0.08]</td>
<td>0.02</td>
<td>0.35</td>
<td></td>
</tr>
<tr>
<td>- Proportion of women</td>
<td>-0.01 [-0.03 to 0.01]</td>
<td>0.01</td>
<td>0.40</td>
<td></td>
</tr>
<tr>
<td>- Outcome measure</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td></td>
</tr>
<tr>
<td>EX:CT</td>
<td>6</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>- Mean age</td>
<td>0.03 [-0.03 to 0.08]</td>
<td>0.02</td>
<td>0.20</td>
<td></td>
</tr>
<tr>
<td>- Mean duration</td>
<td>0.08 [-0.08 to 0.25]</td>
<td>0.06</td>
<td>0.22</td>
<td></td>
</tr>
<tr>
<td>- Proportion of women</td>
<td>0.00 [-0.04 to 0.04]</td>
<td>0.01</td>
<td>0.92</td>
<td></td>
</tr>
<tr>
<td>- Outcome measure</td>
<td>0.63 [-0.48 to 1.74]</td>
<td>0.40</td>
<td>0.19</td>
<td></td>
</tr>
<tr>
<td>EX+AD:AD</td>
<td>4</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>- Mean age</td>
<td>0.01 [-0.06 to 0.09]</td>
<td>0.02</td>
<td>0.54</td>
<td></td>
</tr>
<tr>
<td>- Mean duration</td>
<td>0.04 [-0.09 to 0.18]</td>
<td>0.03</td>
<td>0.28</td>
<td></td>
</tr>
<tr>
<td>- Proportion of women</td>
<td>-0.05 [-0.36 to 0.27]</td>
<td>0.07</td>
<td>0.58</td>
<td></td>
</tr>
<tr>
<td>- Outcome measure</td>
<td>-0.49 [-2.03 to 1.06]</td>
<td>0.36</td>
<td>0.31</td>
<td></td>
</tr>
</tbody>
</table>

*Meta-regression for the EX+AD:EX comparison could not be performed because only one study was available for that comparison.

*Meta-regression for this categorical outcome could not be performed because all studies within this comparison used the same outcome measure.
**eTable 3. Risk of bias for all studies**

<table>
<thead>
<tr>
<th>Study</th>
<th>Randomization process</th>
<th>Deviations from intended interventions</th>
<th>Missing outcome data</th>
<th>Measurement of the outcome</th>
<th>Selection of the reported result</th>
<th>RoB</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bjerkenstedt et al., 2004</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
<td>Some concerns</td>
<td>Some concerns</td>
</tr>
<tr>
<td>Blumenthal et al., 1999</td>
<td>Some concerns</td>
<td>Low</td>
<td>Low</td>
<td>Some concerns</td>
<td>Some concerns</td>
<td>Some concerns</td>
</tr>
<tr>
<td>Blumenthal et al., 2007</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
</tr>
<tr>
<td>Danielsson et al., 2014</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
<td>Some concerns</td>
<td>Some concerns</td>
</tr>
<tr>
<td>Detke et al., 2002</td>
<td>Some concerns</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
</tr>
<tr>
<td>Detke et al., 2004</td>
<td>Some concerns</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
</tr>
<tr>
<td>Dunn et al., 2005</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
<td>Some concerns</td>
<td>Some concerns</td>
</tr>
<tr>
<td>Fava et al., 2005</td>
<td>Some concerns</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
<td>Some concerns</td>
<td>Some concerns</td>
</tr>
<tr>
<td>Gastpar et al., 2005</td>
<td>Some concerns</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
<td>Some concerns</td>
<td>Some concerns</td>
</tr>
<tr>
<td>Goldstein et al., 2004</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
</tr>
<tr>
<td>Hemat-Far et al., 2012</td>
<td>Some concerns</td>
<td>Some concerns</td>
<td>Low</td>
<td>Some concerns</td>
<td>Some concerns</td>
<td>Some concerns</td>
</tr>
<tr>
<td>Hidalgo et al., 2021</td>
<td>Some concerns</td>
<td>Low</td>
<td>Low</td>
<td>Some concerns</td>
<td>Low</td>
<td>Some concerns</td>
</tr>
<tr>
<td>Krogh et al., 2012</td>
<td>Some concerns</td>
<td>High</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
<td>High</td>
</tr>
<tr>
<td>Mao et al., 2015</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
</tr>
<tr>
<td>Mather et al., 2002</td>
<td>Low</td>
<td>Some concerns</td>
<td>Low</td>
<td>Low</td>
<td>Some concerns</td>
<td>Some concerns</td>
</tr>
<tr>
<td>McNeil et al., 1991</td>
<td>Some concerns</td>
<td>Some concerns</td>
<td>Low</td>
<td>Some concerns</td>
<td>Some concerns</td>
<td>Some concerns</td>
</tr>
<tr>
<td>Moreno et al., 2005</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
</tr>
<tr>
<td>Perahia et al., 2006</td>
<td>Some concerns</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
<td>Some concerns</td>
</tr>
<tr>
<td>Philipp et al., 1999</td>
<td>Some concerns</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
<td>Some concerns</td>
<td>Some concerns</td>
</tr>
<tr>
<td>Sadeghi et al., 2016</td>
<td>Some concerns</td>
<td>Low</td>
<td>Some concerns</td>
<td>Low</td>
<td>Low</td>
<td>Some concerns</td>
</tr>
<tr>
<td>Siqueira et al., 2016</td>
<td>Some concerns</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
<td>Some concerns</td>
</tr>
<tr>
<td>Author</td>
<td>Population</td>
<td>Intervention</td>
<td>Outcome</td>
<td>Comparisons</td>
<td>Indirectness</td>
<td></td>
</tr>
<tr>
<td>------------------------</td>
<td>-------------</td>
<td>--------------</td>
<td>-------------</td>
<td>-------------</td>
<td>--------------</td>
<td></td>
</tr>
<tr>
<td>Bjerkenstedt et al., 2005</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
<td>High</td>
<td>Moderate</td>
<td></td>
</tr>
<tr>
<td>Blumenthal et al., 1999</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
<td></td>
</tr>
<tr>
<td>Blumenthal et al., 2007</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
<td></td>
</tr>
<tr>
<td>Danielsson et al., 2014</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
<td></td>
</tr>
<tr>
<td>Detke et al., 2002</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
<td>High</td>
<td>Moderate</td>
<td></td>
</tr>
<tr>
<td>Detke et al., 2004</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
<td>High</td>
<td>Moderate</td>
<td></td>
</tr>
<tr>
<td>Dunn et al., 2005</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
<td>High</td>
<td>Moderate</td>
<td></td>
</tr>
<tr>
<td>Fava et al., 2005</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
<td>High</td>
<td>Moderate</td>
<td></td>
</tr>
<tr>
<td>Gastpar et al., 2006</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
<td>High</td>
<td>Moderate</td>
<td></td>
</tr>
<tr>
<td>Goldstein et al., 2004</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
<td>High</td>
<td>Moderate</td>
<td></td>
</tr>
<tr>
<td>Hemat-Far et al., 2012</td>
<td>High</td>
<td>Female students</td>
<td>Low</td>
<td>Moderate</td>
<td>Self-reported questionnaire</td>
<td>High</td>
</tr>
<tr>
<td>Hidalgo et al., 2021</td>
<td>High</td>
<td>Elderly</td>
<td>Low</td>
<td>Low</td>
<td>Moderate</td>
<td></td>
</tr>
<tr>
<td>Krogh et al., 2012</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
<td>High</td>
<td>Moderate</td>
<td></td>
</tr>
<tr>
<td>Mao et al., 2015</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
<td>High</td>
<td>Moderate</td>
<td></td>
</tr>
<tr>
<td>Mather et al., 2002</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
<td></td>
</tr>
<tr>
<td>McNeil et al., 1991</td>
<td>High</td>
<td>Elderly</td>
<td>Moderate</td>
<td>Somewhat different</td>
<td>Self-reported questionnaire</td>
<td>High</td>
</tr>
<tr>
<td>Moreno et al., 2006</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
<td>High</td>
<td>Moderate</td>
<td></td>
</tr>
<tr>
<td>Perahia et al., 2006</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
<td>High</td>
<td>Moderate</td>
<td></td>
</tr>
<tr>
<td>Philipp et al., 1999</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
<td>High</td>
<td>Moderate</td>
<td></td>
</tr>
<tr>
<td>Sadeghi et al., 2016</td>
<td>Low</td>
<td>Low</td>
<td>Moderate</td>
<td>Self-reported questionnaire</td>
<td>High</td>
<td>Moderate</td>
</tr>
<tr>
<td>Siqueira et al., 2016</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
<td></td>
</tr>
</tbody>
</table>
## eTable 5. Confidence in Network Meta-analysis (CINeMA) final report

<table>
<thead>
<tr>
<th>Comparison</th>
<th>N</th>
<th>Within-study bias</th>
<th>Reporting bias</th>
<th>Indirectness</th>
<th>Imprecision</th>
<th>Heterogeneity</th>
<th>Incoherence</th>
<th>Confidence rating</th>
</tr>
</thead>
<tbody>
<tr>
<td>AD:CT</td>
<td>10</td>
<td>Some concerns</td>
<td>Some concerns</td>
<td>No concerns</td>
<td>Some concerns</td>
<td>No concerns</td>
<td>Moderate</td>
<td></td>
</tr>
<tr>
<td>AD:EX</td>
<td>2</td>
<td>Some concerns</td>
<td>Some concerns</td>
<td>Some concerns</td>
<td>No concerns</td>
<td>No concerns</td>
<td>Moderate</td>
<td></td>
</tr>
<tr>
<td>EX+AD:AD</td>
<td>5</td>
<td>Some concerns</td>
<td>No concerns</td>
<td>Some concerns</td>
<td>No concerns</td>
<td>No concerns</td>
<td>High</td>
<td></td>
</tr>
<tr>
<td>EX:CT</td>
<td>6</td>
<td>Some concerns</td>
<td>Some concerns</td>
<td>No concerns</td>
<td>Some concerns</td>
<td>No concerns</td>
<td>Moderate</td>
<td></td>
</tr>
<tr>
<td>EX+AD:EX</td>
<td>1</td>
<td>Some concerns</td>
<td>No concerns</td>
<td>Some concerns</td>
<td>Some concerns</td>
<td>No concerns</td>
<td>Moderate</td>
<td></td>
</tr>
<tr>
<td>EX+AD:CT</td>
<td>0</td>
<td>Some concerns</td>
<td>Some concerns</td>
<td>No concerns</td>
<td>No concerns</td>
<td>No concerns</td>
<td>High</td>
<td></td>
</tr>
</tbody>
</table>
**eTable 6.** Treatment ranking based on the P-score

<table>
<thead>
<tr>
<th>Treatment</th>
<th>P-score</th>
</tr>
</thead>
<tbody>
<tr>
<td>EX</td>
<td>0.7865</td>
</tr>
<tr>
<td>EX+AD</td>
<td>0.7639</td>
</tr>
<tr>
<td>AD</td>
<td>0.4489</td>
</tr>
<tr>
<td>CT</td>
<td>0.0008</td>
</tr>
</tbody>
</table>
### eTable 7. Assessment of inconsistency within comparisons

<table>
<thead>
<tr>
<th>Comparison</th>
<th>k</th>
<th>Direct</th>
<th>Indirect</th>
<th>Difference</th>
<th>z</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>AD:CT</td>
<td>11</td>
<td>-0.33</td>
<td>-0.38</td>
<td>0.05</td>
<td>0.22</td>
<td>0.83</td>
</tr>
<tr>
<td>AD:EX</td>
<td>3</td>
<td>0.07</td>
<td>0.19</td>
<td>-0.12</td>
<td>-0.52</td>
<td>0.60</td>
</tr>
<tr>
<td>EX+AD:AD</td>
<td>4</td>
<td>0.12</td>
<td>0.09</td>
<td>0.03</td>
<td>0.06</td>
<td>0.95</td>
</tr>
<tr>
<td>EX:CT</td>
<td>6</td>
<td>-0.43</td>
<td>-0.48</td>
<td>0.05</td>
<td>0.21</td>
<td>0.83</td>
</tr>
<tr>
<td>EX+AD:CT</td>
<td>0</td>
<td>NA</td>
<td>-0.45</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>EX+AD:EX</td>
<td>1</td>
<td>-0.18</td>
<td>0.12</td>
<td>-0.30</td>
<td>-0.89</td>
<td>0.38</td>
</tr>
</tbody>
</table>

AD: Antidepressants; CT: Control; EX: Exercise; NA: Not available
### eTable 8. Sensitivity analyses

<table>
<thead>
<tr>
<th>Reasons for exclusion</th>
<th>N</th>
<th>EX-AD</th>
<th>Comb-AD</th>
<th>Comb-EX</th>
<th>Comb-CT</th>
<th>EX-CT</th>
<th>AD-CT</th>
<th>I²</th>
</tr>
</thead>
<tbody>
<tr>
<td>All included</td>
<td>21</td>
<td>-.12 (.33 to .10)</td>
<td>-.12 (.40 to .16)</td>
<td>-.00 (.33 to .33)</td>
<td>-.45 (.76 to -.14)</td>
<td>-.45 (.67 to -.23)</td>
<td>-.33 (.48 to -.19)</td>
<td>46.2%</td>
</tr>
<tr>
<td>Participants older than 60</td>
<td>19</td>
<td>-.10 (.37 to .16)</td>
<td>-.12 (.41 to .17)</td>
<td>-.02 (.37 to .34)</td>
<td>-.44 (.76 to -.12)</td>
<td>-.43 (.69 to -.17)</td>
<td>-.33 (.48 to -.18)</td>
<td>49.0%</td>
</tr>
<tr>
<td>High Risk of Bias</td>
<td>20</td>
<td>-.20 (.40 to .00)</td>
<td>-.13 (.38 to .13)</td>
<td>.07 (.23 to .37)</td>
<td>-.48 (.77 to -.20)</td>
<td>-.56 (.77 to -.34)</td>
<td>-.36 (.49 to -.23)</td>
<td>31.0%</td>
</tr>
<tr>
<td>High Indirectness</td>
<td>19</td>
<td>-.07 (.29 to .15)</td>
<td>-.11 (.39 to .17)</td>
<td>-.04 (.36 to .29)</td>
<td>-.43 (.74 to -.12)</td>
<td>-.39 (.62 to -.16)</td>
<td>-.32 (.46 to -.18)</td>
<td>46.9%</td>
</tr>
<tr>
<td>Intervention longer than 12 weeks</td>
<td>18</td>
<td>-.18 (.58 to .21)</td>
<td>-.29 (.67 to .09)</td>
<td>-.11 (.65 to .44)</td>
<td>-.63 (.105 to -.22)</td>
<td>-.53 (.88 to -.17)</td>
<td>-.35 (.52 to -.17)</td>
<td>52.5%</td>
</tr>
<tr>
<td>SD imputed</td>
<td>16</td>
<td>-.17 (.42 to .09)</td>
<td>-.14 (.45 to .18)</td>
<td>-.03 (.34 to .40)</td>
<td>-.41 (.78 to -.04)</td>
<td>-.44 (.70 to .019)</td>
<td>-.28 (.50 to .05)</td>
<td>50.4%</td>
</tr>
<tr>
<td>Attention/active control comparison</td>
<td>17</td>
<td>-.14 (.35 to .07)</td>
<td>-.09 (.39 to .21)</td>
<td>.05 (.28 to .38)</td>
<td>-.44 (.76 to -.11)</td>
<td>-.48 (.71 to -.25)</td>
<td>-.34 (.47 to -.22)</td>
<td>32.6%</td>
</tr>
<tr>
<td>Passive control comparison</td>
<td>19</td>
<td>-.07 (.29 to .15)</td>
<td>-.11 (.39 to .17)</td>
<td>-.04 (.36 to .29)</td>
<td>-.43 (.74 to -.12)</td>
<td>-.39 (.62 to -.16)</td>
<td>-.32 (.46 to -.18)</td>
<td>46.9%</td>
</tr>
</tbody>
</table>
eAppendix 1. Search strategy

**PubMed**

<table>
<thead>
<tr>
<th>Search</th>
<th>Query</th>
</tr>
</thead>
<tbody>
<tr>
<td>#1</td>
<td>Bupropion[MeSH Terms] OR bupropion[Title/Abstract] OR 34911-55-2[EC/RN Number]</td>
</tr>
<tr>
<td>#2</td>
<td>Citalopram[MeSH Terms] OR citalopram[Title/Abstract] OR 59729-33-8[EC/RN Number]</td>
</tr>
<tr>
<td>#3</td>
<td>escitalopram[Title/Abstract] OR 128196-01-0[EC/RN Number]</td>
</tr>
<tr>
<td>#4</td>
<td>desvenlafaxine[Title/Abstract] OR 386750-22-7[EC/RN Number]</td>
</tr>
<tr>
<td>#5</td>
<td>Fluoxetine[MeSH Terms] OR fluoxetine[Title/Abstract] OR 54910-89-3[EC/RN Number]</td>
</tr>
<tr>
<td>#6</td>
<td>Fluvoxamine[MeSH Terms] OR fluvoxamine[Title/Abstract] OR 54739-18-3[EC/RN Number]</td>
</tr>
<tr>
<td>#7</td>
<td>Milnacipran[Supplementary Concept] OR milnacipran[Title/Abstract] OR levomilnacipran[Title/Abstract]</td>
</tr>
<tr>
<td>#8</td>
<td>Mirtazapine[Supplementary Concept] OR mirtazapine[Title/Abstract] OR 4685R51V7M[EC/RN Number]</td>
</tr>
<tr>
<td>#9</td>
<td>Nefazodone[Supplementary Concept] OR nefazodone[Title/Abstract]</td>
</tr>
<tr>
<td>#10</td>
<td>Paroxetine[MeSH Terms] OR paroxetine[Title/Abstract] OR 61869-08-7[EC/RN Number]</td>
</tr>
<tr>
<td>#11</td>
<td>Sertraline[MeSH Terms] OR sertraline[Title/Abstract] OR 79617-96-2[EC/RN Number]</td>
</tr>
<tr>
<td>#12</td>
<td>Trazodone[MeSH Terms] OR trazodone[Title/Abstract] OR 19794-93-5[EC/RN Number]</td>
</tr>
<tr>
<td>#13</td>
<td>venlafaxine[Title/Abstract] OR 99300-78-4[EC/RN Number]</td>
</tr>
<tr>
<td>#14</td>
<td>vilazodone[Title/Abstract] OR 163521-08-2[EC/RN Number]</td>
</tr>
<tr>
<td>#15</td>
<td>Vortioxetine[Supplementary Concept] OR vortioxetine[Title/Abstract] OR TKS641KOAY[EC/RN Number]</td>
</tr>
<tr>
<td>#16</td>
<td>duloxetine[Title/Abstract] OR 116539-58-3[EC/RN Number]</td>
</tr>
<tr>
<td>#18</td>
<td>#1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14 OR #15 OR #16 OR #17</td>
</tr>
<tr>
<td>#19</td>
<td>Depression, unipolar[MeSH Terms] OR Depressive disorders[MeSH Terms] OR depress*[Title/Abstract]</td>
</tr>
<tr>
<td>#20</td>
<td>Randomized controlled trial[MeSH Terms] OR Random allocation[MeSH Terms] OR (random*[Title/Abstract] AND (control*[Title/Abstract] OR placebo[Title/Abstract]))</td>
</tr>
<tr>
<td>#21</td>
<td>#18 AND #19 AND #20</td>
</tr>
<tr>
<td>#23</td>
<td>#19 AND #20 AND #22</td>
</tr>
<tr>
<td>#24</td>
<td>Adults[MeSH Terms] OR adult*[Title/Abstract]</td>
</tr>
<tr>
<td>#25</td>
<td>#21 AND #24</td>
</tr>
<tr>
<td>#26</td>
<td>#23 AND #24</td>
</tr>
<tr>
<td>#27</td>
<td>#25 OR #26</td>
</tr>
<tr>
<td>#28</td>
<td>Filters: Chinese, English, Italian, from 1990 - 3000/12/12</td>
</tr>
</tbody>
</table>

**PsycINFO**

<table>
<thead>
<tr>
<th>Search</th>
<th>Query</th>
</tr>
</thead>
<tbody>
<tr>
<td>S1</td>
<td>SU(bupropion) OR AB(bupropion) OR TI(bupropion)</td>
</tr>
</tbody>
</table>
S2 SU(citalopram) OR AB(citalopram) OR TI(citalopram)
S3 SU(escitalopram) OR AB(escitalopram) OR TI(escitalopram)
S4 SU(Desvenlafaxine) OR AB(Desvenlafaxine) OR TI(Desvenlafaxine)
S5 SU(Fluoxetine) OR AB(Fluoxetine) OR TI(Fluoxetine)
S6 SU(Fluvoxamine) OR AB(Fluvoxamine) OR TI(Fluvoxamine)
S7 SU(Levomilnacipran) OR AB(Levomilnacipran) OR TI(Levomilnacipran)
S8 SU(mirtazapine) OR AB(mirtazapine) OR TI(mirtazapine)
S9 SU(Nefazodone) OR AB(Nefazodone) OR TI(Nefazodone)
S10 SU(Paroxetine) OR AB(Paroxetine) OR TI(Paroxetine)
S11 SU(Sertraline) OR AB(Sertraline) OR TI(Sertraline)
S12 SU(Trazodone) OR AB(Trazodone) OR TI(Trazodone)
S13 SU(Venlafaxine) OR AB(Venlafaxine) OR TI(Venlafaxine)
S14 SU(vilazodone) OR AB(vilazodone) OR TI(vilazodone)
S15 SU(vortioxetine) OR AB(vortioxetine) OR TI(vortioxetine)
S16 SU(duloxetine) OR AB(duloxetine) OR TI(duloxetine)
S17 SU(Antidepressive Drugs, Second-Generation) OR TI(antidepress*) OR AB(antidepress*)
S18 S1 OR S2 OR S3 OR S4 OR S5 OR S6 OR S7 OR S8 OR S9 OR S10 OR S11 OR S12 OR S13 OR S14 OR S15 OR S16 OR S17
S19 SU(depression) OR SU(depressive disorder) OR TI(depress*) OR AB(depress*)
S20 SU(randomized controlled trial) OR SU(randomized clinical trial) OR SU(random allocation) OR TI(random* AND control*) OR AB(random* AND control*) OR TI(random* AND placebo) OR AB(random* AND placebo)
S21 S18 AND S19 AND S20
S22 SU(adults) OR TI(adult*) OR AB(adult*)
S23 S21 AND S22
S24 SU(exercise) OR TI(exercise) OR AB(exercise) OR SU(physical activity) OR TI(aerobic) OR AB(aerobic) OR TI(training) OR AB(training) OR TI(lift*) OR AB(lift*) OR SU(running) OR TI(running) OR AB(running) OR TI(jogging) OR AB(jogging) OR TI(walk*) OR AB(walk*) OR TI(swim*) OR AB(swim*) OR TI(cycl*) OR AB(cycl*)
S25 S19 AND S20 AND S24
S26 S22 AND S25
S27 S23 AND S26
S28 #27 Limit date range 1990-2021 AND Limit language: English, Chinese, Italian

Cochrane Library

<table>
<thead>
<tr>
<th>ID</th>
<th>Search</th>
</tr>
</thead>
<tbody>
<tr>
<td>#1</td>
<td>bupropion:ti,ab,kw OR [mh bupropion]</td>
</tr>
<tr>
<td>#2</td>
<td>citalopram:ti,ab,kw OR [mh citalopram]</td>
</tr>
<tr>
<td>#3</td>
<td>escitalopram:ti,ab,kw OR [mh escitalopram]</td>
</tr>
<tr>
<td>#4</td>
<td>desvenlafaxine:ti,ab,kw OR [mh desvenlafaxine]</td>
</tr>
<tr>
<td>#5</td>
<td>duloxetine:ti,ab,kw OR [mh duloxetine]</td>
</tr>
<tr>
<td>#6</td>
<td>fluvoxamine:ti,ab,kw OR [mh fluvoxamine]</td>
</tr>
<tr>
<td>#7</td>
<td>levomilnacipran:ti,ab,kw OR [mh levomilnacipran]</td>
</tr>
<tr>
<td>#8</td>
<td>mirtazapine:ti,ab,kw OR [mh mirtazapine]</td>
</tr>
<tr>
<td>#9</td>
<td>nefazodone:ti,ab,kw OR [mh nefazodone]</td>
</tr>
<tr>
<td>#10</td>
<td>Paroxetine:ti,ab,kw OR [mh paroxetine]</td>
</tr>
<tr>
<td>#11</td>
<td>sertraline:ti,ab,kw OR [mh sertraline]</td>
</tr>
<tr>
<td>#12</td>
<td>trazodone:ti,ab,kw OR [mh trazodone]</td>
</tr>
<tr>
<td>#13</td>
<td>venlafaxine:ti,ab OR [mh venlafaxine]</td>
</tr>
<tr>
<td>#14</td>
<td>vilazodone:ti,ab,kw OR [mh vilazodone]</td>
</tr>
<tr>
<td>#15</td>
<td>vortioxetine:ti,ab,kw OR [mh duloxetine]</td>
</tr>
</tbody>
</table>
### Embase

<table>
<thead>
<tr>
<th>#</th>
<th>Searches</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>exp bupropion/ or bupropion.tn,ab.ti. or 34911 55 2.rn.</td>
</tr>
<tr>
<td>2</td>
<td>exp citalopram/ or citalopram.tn,ab.ti. or 59729 33 .rn.</td>
</tr>
<tr>
<td>3</td>
<td>exp escitalopram/ or escitalopram.tn,ab.ti. or 128196 01 0.rn.</td>
</tr>
<tr>
<td>4</td>
<td>exp desvenlafaxine/ or desvenlafaxine.tn,ab.ti. or 93413 62 8.rn.</td>
</tr>
<tr>
<td>5</td>
<td>exp fluoxetine/ or fluoxetine.tn,ab.ti. or 54910 89 3.rn.</td>
</tr>
<tr>
<td>6</td>
<td>exp fluvoxamine/ or fluvoxamine.tn,ab.ti. or 54739 18 3.rn.</td>
</tr>
<tr>
<td>7</td>
<td>exp milnacipran/ or levomilnacipran.tn,ab.ti. or 96847 54 0.rn.</td>
</tr>
<tr>
<td>8</td>
<td>exp mirtazapine/ or mirtazapine.tn,ab.ti. or 85650 52 8.rn.</td>
</tr>
<tr>
<td>9</td>
<td>exp nefazodone/ or nefazodone.tn,ab.ti. or 62752 99 6.rn.</td>
</tr>
<tr>
<td>10</td>
<td>exp paroxetine/ or paroxetine.tn,ab.ti. or 61869 08 7.rn.</td>
</tr>
<tr>
<td>11</td>
<td>exp sertraline/ or sertraline.tn,ab.ti. or 79617 96 2.rn.</td>
</tr>
<tr>
<td>12</td>
<td>exp trazodone/ or trazodone.tn,ab.ti. or 19794 93 5.rn.</td>
</tr>
<tr>
<td>13</td>
<td>exp venlafaxine/ or venlafaxine.tn,ab.ti. or 93413 69 5.rn.</td>
</tr>
<tr>
<td>14</td>
<td>exp vilazodone/ or vilazodone.tn,ab.ti. or 163521 12 8.rn.</td>
</tr>
<tr>
<td>15</td>
<td>exp vortioxetine/ or vortioxetine.tn,ab.ti. or 508233 74 7.rn.</td>
</tr>
<tr>
<td>16</td>
<td>exp duloxetine/ or duloxetine.tn,ab.ti. or 116539 59 4.rn.</td>
</tr>
<tr>
<td>17</td>
<td>exp antidepressant agent/ or antidepress*.ti,ab.</td>
</tr>
<tr>
<td>18</td>
<td>1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17</td>
</tr>
<tr>
<td>19</td>
<td>exp depression/ or exp major depression/ or depress*.ab,ti,kw.</td>
</tr>
<tr>
<td>20</td>
<td>exp randomized controlled trial/ or randomized controlled trial.ti,ab,pt. or randomized</td>
</tr>
<tr>
<td>21</td>
<td>placebo trial.ti,ab. or exp randomization/</td>
</tr>
<tr>
<td>22</td>
<td>exp exercise/ or exercise.ti,ab. or aerobic.ti,ab. or training.ti,ab. or lift*.ti,ab. or</td>
</tr>
<tr>
<td>23</td>
<td>exp depression/ or exp major depression/ or depress*.ab,ti,kw.</td>
</tr>
<tr>
<td>24</td>
<td>exp exercise/ or exercise.ti,ab. or aerobic.ti,ab. or training.ti,ab. or lift*.ti,ab. or</td>
</tr>
<tr>
<td>25</td>
<td>exp exercise/ or exercise.ti,ab. or aerobic.ti,ab. or training.ti,ab. or lift*.ti,ab. or</td>
</tr>
<tr>
<td>26</td>
<td>exp depression/ or exp major depression/ or depress*.ab,ti,kw.</td>
</tr>
<tr>
<td>27</td>
<td>exp exercise/ or exercise.ti,ab. or aerobic.ti,ab. or training.ti,ab. or lift*.ti,ab. or</td>
</tr>
<tr>
<td>28</td>
<td>exp exercise/ or exercise.ti,ab. or aerobic.ti,ab. or training.ti,ab. or lift*.ti,ab. or</td>
</tr>
</tbody>
</table>

### Scopus

<table>
<thead>
<tr>
<th>#</th>
<th>Query</th>
</tr>
</thead>
<tbody>
<tr>
<td>#1</td>
<td>TITLE-ABS-KEY(bupropion OR citalopram OR escitalopram OR desvenlafaxine OR fluoxetine OR fluvoxamine OR milnacipran OR mirtazapine OR nefazodone OR</td>
</tr>
</tbody>
</table>
paroxetine OR sertraline OR trazodone OR venlafaxine OR vilazodone OR vortioxetine OR duloxetine OR antidepress*)

#2 TITLE-ABS-KEY(depress*)
#3 TITLE-ABS-KEY(randomized controlled trial)
#4 TITLE-ABS-KEY(adult*)
#5 #1 AND #2 AND #3 AND #4
#6 TITLE-ABS-KEY(exercise OR 'physical activity' OR aerobic OR training OR lift* OR running OR walk* OR jogging OR swim* OR cycl*)
#7 #2 AND #3 AND #4 AND #6
#8 #5 OR #7

### SportDiscus

<table>
<thead>
<tr>
<th>#1</th>
<th>Query</th>
</tr>
</thead>
<tbody>
<tr>
<td>TS=(bupropion OR citalopram OR escitalopram OR desvenlafaxine OR fluoxetine OR fluvoxamine OR milnacipran OR mirtazapine OR nefazodone OR paroxetine OR sertraline OR trazodone OR venlafaxine OR vilazodone OR vortioxetine OR duloxetine OR antidepress*)</td>
<td></td>
</tr>
<tr>
<td>TS=(depress*)</td>
<td></td>
</tr>
<tr>
<td>TS=(random* AND (control* OR placebo))</td>
<td></td>
</tr>
<tr>
<td>TS=(adult*)</td>
<td></td>
</tr>
<tr>
<td>TS=(exercise OR 'physical activity' OR aerobic OR training OR lift* OR running OR walk* OR jogging OR swim* OR cycl*) OR AB(exercise OR 'physical activity' OR aerobic OR training OR lift* OR running OR walk* OR jogging OR swim* OR cycl*)</td>
<td></td>
</tr>
<tr>
<td>#2 AND #3 AND #4 AND #5</td>
<td></td>
</tr>
</tbody>
</table>

### Web of Science

<table>
<thead>
<tr>
<th>#</th>
<th>Query</th>
</tr>
</thead>
<tbody>
<tr>
<td>#1</td>
<td>TS=(bupropion OR citalopram OR escitalopram OR desvenlafaxine OR fluoxetine OR fluvoxamine OR milnacipran OR mirtazapine OR nefazodone OR paroxetine OR sertraline OR trazodone OR venlafaxine OR vilazodone OR vortioxetine OR duloxetine OR antidepress*)</td>
</tr>
<tr>
<td>#2</td>
<td>TS=(depress*)</td>
</tr>
<tr>
<td>#3</td>
<td>TS=(random* AND (control* OR placebo))</td>
</tr>
<tr>
<td>#4</td>
<td>TS=(adult*)</td>
</tr>
<tr>
<td>#5</td>
<td>TS=(exercise OR 'physical activity' OR aerobic OR training OR lift* OR running OR walk* OR jogging OR swim* OR cycl*)</td>
</tr>
<tr>
<td>#6</td>
<td>#1 AND #2 AND #3 AND #4</td>
</tr>
<tr>
<td>#7</td>
<td>#2 AND #3 AND #4 AND #5</td>
</tr>
<tr>
<td>#8</td>
<td>#6 OR #7</td>
</tr>
</tbody>
</table>
eAppendix 2. Additional methodology information

Risk of bias

The Cochrane risk of bias assessment tool (RoB-2) was used to determine the quality of the individual studies. Bias was assessed in the following domains: 1) randomization process, 2) deviations from the intended interventions, 3) missing outcome data, 4) measurement of the outcome, and 5) selection of the reported results. Each domain was assessed as having either low risk of bias, some concerns, or high risk of bias.

To implement RoB-2, we utilized the Excel template provided in the “Cochrane Handbook for Systematic Reviews of Interventions”, which includes “signalling questions” that can be used to assess bias in each domain. Each domain is automatically evaluated by an algorithm based on the signalling questions, as well as subjectively by the author. To avoid the influence of personal bias, the assessment of each domain was strictly based on the output of the algorithm.

1. Bias due to the randomization process was rated “low” if the study allocation sequence was reported as random and there was evidence that the allocation sequence was concealed. Allocation concealment was considered adequate if the allocation was carried out by investigators that were external to the project, or if authors used a form of remote or centrally administered method that ensured allocation concealment (e.g., sealed opaque envelopes). If the strategy for allocation concealment was not clearly reported, the domain was rated as having “some concerns”. If both categories were deemed to be inadequately described, the domain was rated “high”.

2. Bias due to deviations from the intended interventions was based on whether participants and/or study personnel were blinded to participants’ assigned intervention, whether there were deviations from the intervention due to the trial context, and whether an appropriate analysis was used to estimate the effect of the intervention. Bias was rated “low” if all categories were rated as low. Following the Cochrane algorithm, if participants or study personnel were aware of participants’ allocated intervention but all other categories were considered as low, the domain was still rated as “low”. If there were deviations from the interventions that were suspected to affect the outcome, and if these were not balanced between groups, or if an inappropriate statistical analysis was used that was suspected to substantially impact the outcome, the domain was rated “high”. Any other combination was rated as having “some concerns”.

3. Bias due to missing outcome data was rated “low” if data were available for all, or nearly all, participants randomized. If there was the possibility that missingness in the outcome was influenced by its true value, the domain was rated “some concerns”. If missingness in the outcome was likely influenced by its true value, the domain was rated “high”.

4. Bias in measurement of the outcome was rated “high” if the method for measuring the outcome was inappropriate, if it differed between groups, or if it was likely that the assessment was influenced by knowledge of the intervention. It was rated “some concerns” if outcome assessors were aware of the intervention received by participants, but it was not likely that assignment was influenced by knowledge of the intervention. Bias in measurement of the outcome was rated “low” if all categories were considered as low.

5. Bias in selection of the reported result was rated “low” if it was unlikely that the results were selected from multiple measurements or analyses, and data were analysed in accordance with a pre-specified plan. If no pre-specified plan was available but it was unlikely that results were selected from multiple measurements or analyses, the domain was rated “some concerns”. If it was suspected that results were selected from multiple measurements or analyses, the domain was rated “high”.

17
Overall risk of bias was rated “low” if all domains were rated “low”, it was rated “some concerns” if the study was judged to raise some concerns in at least one domain, but not to be at high risk of bias for any domain, and it was was rated “high” if at least one domain was considered as “high”.

Confidence of Network Meta-analysis (CINeMA) rating

We used the CINeMA framework to assess the overall credibility of the results. CINeMA is based on the following domains: 1) within-study bias, 2) reporting bias, 3) indirectness, 4) imprecision, 5) heterogeneity, and 6) incoherence. Within-study bias was evaluated using the RoB-2 tool. Reporting bias for each comparison was coded as “suspected” or “undetected” based on the completeness of the research and availability of published data. Indirectness was assessed as described below. To assess imprecision, heterogeneity, and incoherence, we set the clinically significant effect size to 0.35.

Indirectness

Indirectness was assessed based on recommended guidelines. We evaluated whether studies differed in relation to 1) population, 2) intervention, 3) outcome, and 4) whether a study showed direct evidence for at least one comparison of interest. Study indirectness was coded as “low” if three or more outcomes were considered to be “low” and no more than one was “unclear”, and coded as “high” if two or more outcomes were considered to be “high”, whereas any other combination was coded as “moderate”.

### eAppendix 3. Pairwise meta-analyses

#### Comparative effectiveness on depressive symptoms from pairwise meta-analyses

<table>
<thead>
<tr>
<th>Study</th>
<th>Exercise Total Mean</th>
<th>Antidepressants Total Mean</th>
<th>Standardised Mean Difference</th>
<th>SMD</th>
<th>95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Blumenthal(2007)</td>
<td>51 9.29 6.000</td>
<td>49 10.20 6.0380</td>
<td>-0.15</td>
<td>0.04</td>
<td>0.24</td>
</tr>
<tr>
<td>Hidage(2011)</td>
<td>175 3.35 5.1300</td>
<td>171 5.85 5.4000</td>
<td>-0.10</td>
<td>0.01</td>
<td>0.11</td>
</tr>
<tr>
<td>Blumenthal(1999)</td>
<td>53 8.10 5.5419</td>
<td>48 7.80 5.5916</td>
<td>0.05</td>
<td>0.04</td>
<td>0.04</td>
</tr>
<tr>
<td><strong>Random effects model</strong></td>
<td>280</td>
<td>268</td>
<td>-0.08</td>
<td>0.29</td>
<td>0.12</td>
</tr>
</tbody>
</table>

*Heterogeneity: τ² = 0.007, p = 0.75*

<table>
<thead>
<tr>
<th>Study</th>
<th>Exercise Total Mean</th>
<th>Control Total Mean</th>
<th>Standardised Mean Difference</th>
<th>SMD</th>
<th>95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dorr(2009)</td>
<td>17 9.00 3.0000</td>
<td>13 14.00 4.9000</td>
<td>-1.16</td>
<td>-1.04</td>
<td>-0.27</td>
</tr>
<tr>
<td>McCall(1991)</td>
<td>10 11.10 3.0000</td>
<td>10 14.70 3.0000</td>
<td>-1.02</td>
<td>-0.97</td>
<td>0.08</td>
</tr>
<tr>
<td>Homel F(2012)</td>
<td>10 16.00 6.000</td>
<td>10 12.60 9.000</td>
<td>-0.99</td>
<td>-1.00</td>
<td>0.05</td>
</tr>
<tr>
<td>Savastri(2009)</td>
<td>16 13.31 5.6000</td>
<td>14 16.35 6.4000</td>
<td>-0.95</td>
<td>-1.01</td>
<td>0.08</td>
</tr>
<tr>
<td>Blumenthal(2007)</td>
<td>51 9.20 6.0525</td>
<td>49 11.00 6.7180</td>
<td>-0.27</td>
<td>0.96</td>
<td>0.13</td>
</tr>
<tr>
<td>Koeh(2012)</td>
<td>50 11.30 6.0000</td>
<td>50 10.90 6.4000</td>
<td>0.12</td>
<td>0.29</td>
<td>0.49</td>
</tr>
<tr>
<td><strong>Random effects model</strong></td>
<td>160</td>
<td>165</td>
<td>-0.08</td>
<td>-1.14</td>
<td>-0.01</td>
</tr>
</tbody>
</table>

*Heterogeneity: τ² = 0.003, p = 0.01*

### Study: Antidepressants vs Exercise and Control

<table>
<thead>
<tr>
<th>Study</th>
<th>Antidepressants Total Mean</th>
<th>Exercise Total Mean</th>
<th>Standardised Mean Difference</th>
<th>SMD</th>
<th>95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Moreno(2006)</td>
<td>20 6.70 3.9900</td>
<td>20 10.90 5.0154</td>
<td>-0.88</td>
<td>1.45</td>
<td>0.36</td>
</tr>
<tr>
<td>Delfino(2014)</td>
<td>93 8.10 5.7500</td>
<td>93 11.10 5.6200</td>
<td>-0.53</td>
<td>0.62</td>
<td>0.23</td>
</tr>
<tr>
<td>Cedrasia(2014)</td>
<td>86 9.30 5.7500</td>
<td>89 12.30 5.6200</td>
<td>-0.51</td>
<td>0.81</td>
<td>0.21</td>
</tr>
<tr>
<td>Philips(1996)</td>
<td>105 8.00 5.7500</td>
<td>46 10.00 5.6200</td>
<td>-0.46</td>
<td>0.80</td>
<td>0.16</td>
</tr>
<tr>
<td>Capser(2000)</td>
<td>127 10.30 4.0000</td>
<td>130 13.00 6.0000</td>
<td>-0.40</td>
<td>0.65</td>
<td>0.16</td>
</tr>
<tr>
<td>Defino(2003)</td>
<td>128 9.00 5.7500</td>
<td>139 12.50 5.6200</td>
<td>-0.40</td>
<td>0.65</td>
<td>0.16</td>
</tr>
<tr>
<td>Max(2015)</td>
<td>17 7.90 2.6020</td>
<td>18 8.60 3.1055</td>
<td>-0.24</td>
<td>0.48</td>
<td>0.41</td>
</tr>
<tr>
<td>Peronaci(2006)</td>
<td>102 9.00 5.7700</td>
<td>96 9.80 5.6200</td>
<td>-0.14</td>
<td>0.42</td>
<td>0.14</td>
</tr>
<tr>
<td>Blumenthal(2007)</td>
<td>49 10.20 6.5600</td>
<td>49 11.00 6.7180</td>
<td>-0.12</td>
<td>0.62</td>
<td>0.28</td>
</tr>
<tr>
<td>Bjorkqvist(2005)</td>
<td>54 14.00 6.4000</td>
<td>55 15.50 6.7000</td>
<td>-0.08</td>
<td>0.45</td>
<td>0.30</td>
</tr>
<tr>
<td>Fazza(2005)</td>
<td>47 13.30 7.3000</td>
<td>43 12.00 6.4000</td>
<td>0.10</td>
<td>0.31</td>
<td>0.51</td>
</tr>
<tr>
<td><strong>Random effects model</strong></td>
<td>830</td>
<td>787</td>
<td>-0.33</td>
<td>0.49</td>
<td>0.16</td>
</tr>
</tbody>
</table>

*Heterogeneity: τ² = 0.38, p = 0.040, p = 0.10*

### Study: Combination vs Exercise and Control

<table>
<thead>
<tr>
<th>Study</th>
<th>Combination Total Mean</th>
<th>Exercise Total Mean</th>
<th>Standardised Mean Difference</th>
<th>SMD</th>
<th>95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Danielsson(2014)</td>
<td>22 14.00 8.4717</td>
<td>20 18.50 8.4200</td>
<td>-0.52</td>
<td>1.14</td>
<td>0.09</td>
</tr>
<tr>
<td>Sjumma(2015)</td>
<td>29 11.38 5.9400</td>
<td>28 12.64 5.7400</td>
<td>-0.25</td>
<td>0.77</td>
<td>0.27</td>
</tr>
<tr>
<td>Nether(2010)</td>
<td>43 12.00 6.5000</td>
<td>43 13.70 6.5000</td>
<td>-0.17</td>
<td>0.59</td>
<td>0.29</td>
</tr>
<tr>
<td>Blumenthal(1999)</td>
<td>55 9.30 7.0342</td>
<td>48 7.80 5.5916</td>
<td>0.23</td>
<td>0.86</td>
<td>0.02</td>
</tr>
<tr>
<td><strong>Random effects model</strong></td>
<td>140</td>
<td>139</td>
<td>-0.13</td>
<td>0.63</td>
<td>0.36</td>
</tr>
</tbody>
</table>

*Heterogeneity: τ² = 0.41, p = 0.004, p = 0.17*

<table>
<thead>
<tr>
<th>Study</th>
<th>Combination Total Mean</th>
<th>Exercise Total Mean</th>
<th>Standardised Mean Difference</th>
<th>SMD</th>
<th>95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Blumenthal(1999)</td>
<td>55 9.30 7.0342</td>
<td>53 10.10 6.5419</td>
<td>-0.18</td>
<td>0.20</td>
<td>0.55</td>
</tr>
</tbody>
</table>

*Heterogeneity: τ² = 0.004, p = 0.17*
### Comparative effectiveness on acceptability from pairwise meta-analyses

#### EX

<table>
<thead>
<tr>
<th>Study</th>
<th>Events Total</th>
<th>Events Total</th>
<th>Risk Ratio</th>
<th>RR 95%-CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hidalgo(2021)</td>
<td>110</td>
<td>78</td>
<td>1.37</td>
<td>[1.12; 1.67]</td>
</tr>
<tr>
<td>Blumenthal(2007)</td>
<td>10</td>
<td>7</td>
<td>1.37</td>
<td>[0.57; 3.32]</td>
</tr>
<tr>
<td>Blumenthal(1999)</td>
<td>14</td>
<td>7</td>
<td>1.61</td>
<td>[0.80; 3.24]</td>
</tr>
</tbody>
</table>

**Random effects model**

- N: 280
- Estimate: 1.40
- 95% CI: [1.13; 1.72]

#### AD

<table>
<thead>
<tr>
<th>Study</th>
<th>Events Total</th>
<th>Events Total</th>
<th>Risk Ratio</th>
<th>RR 95%-CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Deeks(2004)</td>
<td>7</td>
<td>17</td>
<td>0.67</td>
<td>[0.33; 1.38]</td>
</tr>
<tr>
<td>Knight(2001)</td>
<td>10</td>
<td>14</td>
<td>0.93</td>
<td>[0.34; 1.40]</td>
</tr>
<tr>
<td>Knight(2012)</td>
<td>9</td>
<td>6</td>
<td>1.58</td>
<td>[0.89; 2.85]</td>
</tr>
</tbody>
</table>

**Random effects model**

- N: 124
- Estimate: 0.84
- 95% CI: [0.27; 2.58]

#### CT

<table>
<thead>
<tr>
<th>Study</th>
<th>Events Total</th>
<th>Events Total</th>
<th>Risk Ratio</th>
<th>RR 95%-CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Blumenthal(2007)</td>
<td>7</td>
<td>14</td>
<td>0.50</td>
<td>[0.22; 1.13]</td>
</tr>
<tr>
<td>Deeks(2004)</td>
<td>4</td>
<td>9</td>
<td>0.74</td>
<td>[0.25; 2.19]</td>
</tr>
<tr>
<td>Deeks(2005)</td>
<td>5</td>
<td>7</td>
<td>0.74</td>
<td>[0.25; 2.19]</td>
</tr>
<tr>
<td>Deeks(2006)</td>
<td>4</td>
<td>7</td>
<td>0.84</td>
<td>[0.57; 1.27]</td>
</tr>
<tr>
<td>Deeks(2008)</td>
<td>23</td>
<td>25</td>
<td>0.90</td>
<td>[0.70; 1.14]</td>
</tr>
<tr>
<td>Deeks(2009)</td>
<td>38</td>
<td>37</td>
<td>1.00</td>
<td>[0.71; 1.42]</td>
</tr>
<tr>
<td>Deeks(2010)</td>
<td>50</td>
<td>49</td>
<td>1.11</td>
<td>[0.81; 1.51]</td>
</tr>
<tr>
<td>Deeks(2011)</td>
<td>20</td>
<td>18</td>
<td>1.13</td>
<td>[0.87; 1.46]</td>
</tr>
<tr>
<td>Deeks(2012)</td>
<td>110</td>
<td>0</td>
<td>1.29</td>
<td>[0.65; 2.51]</td>
</tr>
<tr>
<td>Deeks(2013)</td>
<td>13</td>
<td>9</td>
<td>1.39</td>
<td>[0.62; 3.20]</td>
</tr>
</tbody>
</table>

**Random effects model**

- N: 845
- Estimate: 0.97
- 95% CI: [0.84; 1.13]

#### Combin

<table>
<thead>
<tr>
<th>Study</th>
<th>Events Total</th>
<th>Events Total</th>
<th>Risk Ratio</th>
<th>RR 95%-CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Deeks(2014)</td>
<td>4</td>
<td>20</td>
<td>0.61</td>
<td>[0.29; 1.35]</td>
</tr>
<tr>
<td>Deeks(2015)</td>
<td>9</td>
<td>20</td>
<td>1.59</td>
<td>[0.49; 5.41]</td>
</tr>
<tr>
<td>Blumenthal(1999)</td>
<td>11</td>
<td>4</td>
<td>1.37</td>
<td>[0.58; 3.32]</td>
</tr>
</tbody>
</table>

**Random effects model**

- N: 106
- Estimate: 1.63
- 95% CI: [0.40; 6.93]

#### EX

<table>
<thead>
<tr>
<th>Study</th>
<th>Events Total</th>
<th>Events Total</th>
<th>Risk Ratio</th>
<th>RR 95%-CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Blumenthal(1999)</td>
<td>11</td>
<td>14</td>
<td>0.76</td>
<td>[0.38; 1.52]</td>
</tr>
</tbody>
</table>

20
eAppendix 4. References


Comparative effectiveness of exercise, antidepressants, and their combination in treating non-severe depression: A systematic review and network meta-analysis of randomized controlled trials

Supplementary Online Content

eFigure 1. PRISMA flow chart
eFigure 2. Risk of bias contributions
eFigure 3. Indirectness contributions
eTable 1. Distribution of study characteristics
eTable 2. Meta-regression for direct comparisons
eTable 3. Risk of bias for all studies
eTable 4. Indirectness for all studies
eTable 5. Confidence in Network Meta-analysis (CINeMA) final report
eTable 6. Treatment ranking based on the P-score
eTable 7. Assessment of inconsistency within comparisons
eTable 8. Sensitivity analyses
eAppendix 1. Search strategy
eAppendix 2. Additional methodology information
eAppendix 3. Pairwise meta-analyses
eAppendix 4. References
**eFigure 1. PRISMA flow chart**

**Identification**
- Records identified from:
  - PubMed (n = 5,911)
  - PsycInfo (n = 3,572)
  - Embase (n = 13,493)
  - Cochrane Library (n = 5,880)
  - Scopus (n = 12,288)
  - SportDiscus (n = 35)
  - Web of Science (n = 4,858)

**Screening**
- Records screened (n = 23,209)
- Records excluded (n = 22,880)
- Reports not retrieved (n = 0)

**Inclusion**
- Reports not retrieved (n = 0)
- Reports assessed for eligibility (n = 329)
- Reports excluded:
  - Ineligible population (n = 202)
  - Ineligible or no comparison (n = 33)
  - Ineligible study design (n = 24)
  - Ineligible outcome (n = 13)
  - Abstract only (n = 12)
  - Secondary publication (n = 29)
- Reports assessed for eligibility (n = 56)
- Reports excluded:
  - Ineligible population (n = 31)
  - Ineligible intervention (n = 9)
  - Ineligible study design (n = 7)
  - Ineligible or no comparison (n = 4)
- Reports included in meta-analysis (n = 21)
eFigure 2. Risk of bias contributions
eFigure 3. Indirectness contributions
**eTable 1. Distribution of study characteristics**

<table>
<thead>
<tr>
<th>Comparison</th>
<th>N studies</th>
<th>Participant age (years)</th>
<th>Sex (% women)</th>
<th>Intervention duration (weeks)</th>
<th>Outcome measure</th>
</tr>
</thead>
<tbody>
<tr>
<td>EX:AD</td>
<td>3</td>
<td>&lt; 60</td>
<td>≥ 50%</td>
<td>19</td>
<td>HAM-D</td>
</tr>
<tr>
<td>AD:CT</td>
<td>11</td>
<td>&lt; 60</td>
<td>≥ 50%</td>
<td>9</td>
<td>HAM-D</td>
</tr>
<tr>
<td>EX:CT</td>
<td>6</td>
<td>&lt; 60</td>
<td>≥ 50%</td>
<td>10</td>
<td>HAM-D</td>
</tr>
<tr>
<td>EX+AD:AD</td>
<td>4</td>
<td>&lt; 60</td>
<td>≥ 50%</td>
<td>11</td>
<td>HAM-D</td>
</tr>
<tr>
<td>EX+AD:EX</td>
<td>1</td>
<td>&lt; 60</td>
<td>≥ 50%</td>
<td>16</td>
<td>HAM-D</td>
</tr>
</tbody>
</table>
# eTable 2. Meta-regression for direct comparisons

<table>
<thead>
<tr>
<th>Comparison</th>
<th>N</th>
<th>Coefficient [95% CI]</th>
<th>SE</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>EX:AD</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>- Mean age</td>
<td>3</td>
<td>-0.00 [-0.16 to 0.16]</td>
<td>0.01</td>
<td>0.94</td>
</tr>
<tr>
<td>- Mean duration</td>
<td>-0.01 [-0.21 to 0.20]</td>
<td>0.02</td>
<td>0.75</td>
<td></td>
</tr>
<tr>
<td>- Proportion of women</td>
<td>-0.02 [-0.39 to 0.36]</td>
<td>0.03</td>
<td>0.67</td>
<td></td>
</tr>
<tr>
<td>- Outcome measure</td>
<td>-0.05 [-1.68 to 1.58]</td>
<td>0.13</td>
<td>0.75</td>
<td></td>
</tr>
<tr>
<td>AD:CT</td>
<td>11</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>- Mean age</td>
<td>11</td>
<td>0.01 [-0.03 to 0.05]</td>
<td>0.02</td>
<td>0.70</td>
</tr>
<tr>
<td>- Mean duration</td>
<td>0.02 [-0.03 to 0.08]</td>
<td>0.02</td>
<td>0.35</td>
<td></td>
</tr>
<tr>
<td>- Proportion of women</td>
<td>-0.01 [-0.03 to 0.01]</td>
<td>0.01</td>
<td>0.40</td>
<td></td>
</tr>
<tr>
<td>- Outcome measure b</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td></td>
</tr>
<tr>
<td>EX:CT</td>
<td>6</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>- Mean age</td>
<td>6</td>
<td>0.03 [-0.03 to 0.08]</td>
<td>0.02</td>
<td>0.20</td>
</tr>
<tr>
<td>- Mean duration</td>
<td>0.08 [-0.08 to 0.25]</td>
<td>0.06</td>
<td>0.22</td>
<td></td>
</tr>
<tr>
<td>- Proportion of women</td>
<td>0.00 [-0.04 to 0.04]</td>
<td>0.01</td>
<td>0.92</td>
<td></td>
</tr>
<tr>
<td>- Outcome measure</td>
<td>0.63 [-0.48 to 1.74]</td>
<td>0.40</td>
<td>0.19</td>
<td></td>
</tr>
<tr>
<td>EX+AD:AD</td>
<td>4</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>- Mean age</td>
<td>4</td>
<td>0.01 [-0.06 to 0.09]</td>
<td>0.02</td>
<td>0.54</td>
</tr>
<tr>
<td>- Mean duration</td>
<td>0.04 [-0.09 to 0.18]</td>
<td>0.03</td>
<td>0.28</td>
<td></td>
</tr>
<tr>
<td>- Proportion of women</td>
<td>-0.05 [-0.36 to 0.27]</td>
<td>0.07</td>
<td>0.58</td>
<td></td>
</tr>
<tr>
<td>- Outcome measure</td>
<td>-0.49 [-2.03 to 1.06]</td>
<td>0.36</td>
<td>0.31</td>
<td></td>
</tr>
</tbody>
</table>

*Meta-regression for the EX+AD:EX comparison could not be performed because only one study was available for that comparison

bMeta-regression for this categorical outcome could not be performed because all studies within this comparison used the same outcome measure
**eTable 3. Risk of bias for all studies**

<table>
<thead>
<tr>
<th>Study</th>
<th>Randomization process</th>
<th>Deviations from intended interventions</th>
<th>Missing outcome data</th>
<th>Measurement of the outcome</th>
<th>Selection of the reported result</th>
<th>RoB</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bjerkenstedt et al., 2004</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
<td>Some concerns</td>
<td>Some concerns</td>
</tr>
<tr>
<td>Blumenthal et al., 1999</td>
<td>Some concerns</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
<td>Some concerns</td>
<td>Some concerns</td>
</tr>
<tr>
<td>Blumenthal et al., 2007</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
</tr>
<tr>
<td>Danielsson et al., 2014</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
<td>Some concerns</td>
<td>Some concerns</td>
<td>Some concerns</td>
</tr>
<tr>
<td>Detke et al., 2002</td>
<td>Some concerns</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
<td>Some concerns</td>
</tr>
<tr>
<td>Detke et al., 2004</td>
<td>Some concerns</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
<td>Some concerns</td>
</tr>
<tr>
<td>Dunn et al., 2005</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
</tr>
<tr>
<td>Fava et al., 2005</td>
<td>Some concerns</td>
<td>Low</td>
<td>Low</td>
<td>Some concerns</td>
<td>Some concerns</td>
<td>Some concerns</td>
</tr>
<tr>
<td>Gastpar et al., 2005</td>
<td>Some concerns</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
<td>Some concerns</td>
</tr>
<tr>
<td>Goldstein et al., 2004</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
</tr>
<tr>
<td>Hidalgro et al., 2021</td>
<td>Some concerns</td>
<td>Some concerns</td>
<td>Low</td>
<td>Some concerns</td>
<td>Some concerns</td>
<td>Some concerns</td>
</tr>
<tr>
<td>Krogh et al., 2012</td>
<td>Some concerns</td>
<td>High</td>
<td>Low</td>
<td>Some concerns</td>
<td>Low</td>
<td>High</td>
</tr>
<tr>
<td>Mao et al., 2015</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
</tr>
<tr>
<td>Mather et al., 2002</td>
<td>Low</td>
<td>Some concerns</td>
<td>Low</td>
<td>Low</td>
<td>Some concerns</td>
<td>Some concerns</td>
</tr>
<tr>
<td>McNeil et al., 1991</td>
<td>Some concerns</td>
<td>Some concerns</td>
<td>Low</td>
<td>Some concerns</td>
<td>Some concerns</td>
<td>Some concerns</td>
</tr>
<tr>
<td>Moreno et al., 2005</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
</tr>
<tr>
<td>Perahia et al., 2006</td>
<td>Some concerns</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
<td>Some concerns</td>
</tr>
<tr>
<td>Philipp et al., 1999</td>
<td>Some concerns</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
<td>Some concerns</td>
</tr>
<tr>
<td>Sadeghi et al., 2016</td>
<td>Some concerns</td>
<td>Low</td>
<td>Some concerns</td>
<td>Low</td>
<td>Low</td>
<td>Some concerns</td>
</tr>
<tr>
<td>Siqueira et al., 2016</td>
<td>Some concerns</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
<td>Some concerns</td>
</tr>
</tbody>
</table>
eTable 4. Indirectness for all studies

<table>
<thead>
<tr>
<th>Author</th>
<th>Population</th>
<th>Intervention</th>
<th>Outcome</th>
<th>Comparisons</th>
<th>Indirectness</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bjerkenstedt et al., 2005</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
<td>High</td>
<td>Moderate</td>
</tr>
<tr>
<td>Blumenthal et al., 1999</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
</tr>
<tr>
<td>Blumenthal et al., 2007</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
</tr>
<tr>
<td>Danielsson et al., 2014</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
</tr>
<tr>
<td>Detke et al., 2002</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
<td>High</td>
<td>Moderate</td>
</tr>
<tr>
<td>Detke et al., 2004</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
<td>High</td>
<td>Moderate</td>
</tr>
<tr>
<td>Dunn et al., 2005</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
<td>High</td>
<td>Moderate</td>
</tr>
<tr>
<td>Fava et al., 2005</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
<td>High</td>
<td>Moderate</td>
</tr>
<tr>
<td>Gastpar et al., 2006</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
<td>High</td>
<td>Moderate</td>
</tr>
<tr>
<td>Goldstein et al., 2004</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
<td>High</td>
<td>Moderate</td>
</tr>
<tr>
<td>Hemat-Far et al., 2012</td>
<td>High</td>
<td>Female students</td>
<td>Low</td>
<td>Moderate</td>
<td>Self-reported questionnaire</td>
</tr>
<tr>
<td>Hidalgo et al., 2021</td>
<td>High</td>
<td>Elderly</td>
<td>Low</td>
<td>Low</td>
<td>Moderate</td>
</tr>
<tr>
<td>Krogh et al., 2012</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
<td>High</td>
<td>Moderate</td>
</tr>
<tr>
<td>Mao et al., 2015</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
<td>High</td>
<td>Moderate</td>
</tr>
<tr>
<td>Mather et al., 2002</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
</tr>
<tr>
<td>McNeil et al., 1991</td>
<td>High</td>
<td>Elderly</td>
<td>Moderate</td>
<td>Somewhat different</td>
<td>Moderate</td>
</tr>
<tr>
<td>Moreno et al., 2006</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
<td>High</td>
<td>Moderate</td>
</tr>
<tr>
<td>Perahia et al., 2006</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
<td>High</td>
<td>Moderate</td>
</tr>
<tr>
<td>Philipp et al., 1999</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
<td>High</td>
<td>Moderate</td>
</tr>
<tr>
<td>Sadeghi et al., 2016</td>
<td>Low</td>
<td>Low</td>
<td>Moderate</td>
<td>Self-reported questionnaire</td>
<td>High</td>
</tr>
<tr>
<td>Siqueira et al., 2016</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
</tr>
</tbody>
</table>
**eTable 5. Confidence in Network Meta-analysis (CINeMA) final report**

<table>
<thead>
<tr>
<th>Comparison</th>
<th>N</th>
<th>Within-study bias</th>
<th>Reporting bias</th>
<th>Indirectness</th>
<th>Imprecision</th>
<th>Heterogeneity</th>
<th>Incoherence</th>
<th>Confidence rating</th>
</tr>
</thead>
<tbody>
<tr>
<td>AD:CT</td>
<td>10</td>
<td>Some concerns</td>
<td>Some concerns</td>
<td>No concerns</td>
<td>Some concerns</td>
<td>No concerns</td>
<td>No concerns</td>
<td>Moderate</td>
</tr>
<tr>
<td>AD:EX</td>
<td>2</td>
<td>Some concerns</td>
<td>Some concerns</td>
<td>Some concerns</td>
<td>No concerns</td>
<td>No concerns</td>
<td>No concerns</td>
<td>Moderate</td>
</tr>
<tr>
<td>EX+AD:AD</td>
<td>5</td>
<td>Some concerns</td>
<td>Some concerns</td>
<td>No concerns</td>
<td>Some concerns</td>
<td>No concerns</td>
<td>No concerns</td>
<td>High</td>
</tr>
<tr>
<td>EX:CT</td>
<td>6</td>
<td>Some concerns</td>
<td>Some concerns</td>
<td>No concerns</td>
<td>Some concerns</td>
<td>No concerns</td>
<td>No concerns</td>
<td>Moderate</td>
</tr>
<tr>
<td>EX+AD:EX</td>
<td>1</td>
<td>Some concerns</td>
<td>Some concerns</td>
<td>No concerns</td>
<td>Some concerns</td>
<td>No concerns</td>
<td>No concerns</td>
<td>Moderate</td>
</tr>
<tr>
<td>EX+AD:CT</td>
<td>0</td>
<td>Some concerns</td>
<td>Some concerns</td>
<td>No concerns</td>
<td>No concerns</td>
<td>No concerns</td>
<td>No concerns</td>
<td>High</td>
</tr>
</tbody>
</table>
### eTable 6. Treatment ranking based on the P-score

<table>
<thead>
<tr>
<th>Treatment</th>
<th>P-score</th>
</tr>
</thead>
<tbody>
<tr>
<td>EX</td>
<td>0.7865</td>
</tr>
<tr>
<td>EX+AD</td>
<td>0.7639</td>
</tr>
<tr>
<td>AD</td>
<td>0.4489</td>
</tr>
<tr>
<td>CT</td>
<td>0.0008</td>
</tr>
</tbody>
</table>
**eTable 7. Assessment of inconsistency within comparisons**

<table>
<thead>
<tr>
<th>Comparison</th>
<th>k</th>
<th>Direct</th>
<th>Indirect</th>
<th>Difference</th>
<th>z</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>AD:CT</td>
<td>11</td>
<td>-0.33</td>
<td>-0.38</td>
<td>0.05</td>
<td>0.22</td>
<td>0.83</td>
</tr>
<tr>
<td>AD:EX</td>
<td>3</td>
<td>0.07</td>
<td>0.19</td>
<td>-0.12</td>
<td>-0.52</td>
<td>0.60</td>
</tr>
<tr>
<td>EX+AD:AD</td>
<td>4</td>
<td>0.12</td>
<td>0.09</td>
<td>0.03</td>
<td>0.06</td>
<td>0.95</td>
</tr>
<tr>
<td>EX:CT</td>
<td>6</td>
<td>-0.43</td>
<td>-0.48</td>
<td>0.05</td>
<td>0.21</td>
<td>0.83</td>
</tr>
<tr>
<td>EX+AD:CT</td>
<td>0</td>
<td>NA</td>
<td>-0.45</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>EX+AD:EX</td>
<td>1</td>
<td>-0.18</td>
<td>0.12</td>
<td>-0.30</td>
<td>-0.89</td>
<td>0.38</td>
</tr>
</tbody>
</table>

AD: Antidepressants; CT: Control; EX: Exercise; NA: Not available
### eTable 8. Sensitivity analyses

<table>
<thead>
<tr>
<th>Reasons for exclusion</th>
<th>N</th>
<th>EX-AD</th>
<th>Comb-AD</th>
<th>Comb-EX</th>
<th>Comb-CT</th>
<th>EX-CT</th>
<th>AD-CT</th>
<th>I²</th>
</tr>
</thead>
<tbody>
<tr>
<td>All included</td>
<td>21</td>
<td>-.12 (-.33 to .10)</td>
<td>-.12 (-.40 to .16)</td>
<td>-.00 (-.33 to .33)</td>
<td>-.45 (-.76 to -.14)</td>
<td>-.45 (-.67 to -.23)</td>
<td>-.33 (-.48 to -.19)</td>
<td>46.2%</td>
</tr>
<tr>
<td>Participants older than 60</td>
<td>19</td>
<td>-.10 (-.37 to .16)</td>
<td>-.12 (-.41 to .17)</td>
<td>-.02 (-.37 to .34)</td>
<td>-.44 (-.76 to -.12)</td>
<td>-.43 (-.69 to -.17)</td>
<td>-.33 (-.48 to -.18)</td>
<td>49.0%</td>
</tr>
<tr>
<td>High Risk of Bias</td>
<td>20</td>
<td>-.20 (-.40 to .00)</td>
<td>-.13 (-.38 to .13)</td>
<td>.07 (-.23 to .37)</td>
<td>-.48 (-.77 to -.20)</td>
<td>-.56 (-.77 to -.34)</td>
<td>-.36 (-.49 to -.23)</td>
<td>31.0%</td>
</tr>
<tr>
<td>High Indirectness</td>
<td>19</td>
<td>-.07 (-.29 to .15)</td>
<td>-.11 (-.39 to .17)</td>
<td>-.04 (-.36 to .29)</td>
<td>-.43 (-.74 to -.12)</td>
<td>-.39 (-.62 to -.16)</td>
<td>-.32 (-.46 to -.18)</td>
<td>46.9%</td>
</tr>
<tr>
<td>Intervention longer than 12 weeks</td>
<td>18</td>
<td>-.18 (-.58 to .21)</td>
<td>-.29 (-.67 to .09)</td>
<td>-.11 (-.65 to .44)</td>
<td>-.63 (-1.05 to -.22)</td>
<td>-.53 (-.88 to -.17)</td>
<td>-.35 (-.52 to -.17)</td>
<td>52.5%</td>
</tr>
<tr>
<td>SD imputed</td>
<td>16</td>
<td>-.17 (-.42 to .09)</td>
<td>-.14 (-.45 to .18)</td>
<td>-.03 (-.34 to .40)</td>
<td>-.41 (-.78 to -.04)</td>
<td>-.44 (-.70 to 0.19)</td>
<td>-.28 (-.50 to .05)</td>
<td>50.4%</td>
</tr>
<tr>
<td>Attention/active control comparison</td>
<td>17</td>
<td>-.14 (-.35 to .07)</td>
<td>-.09 (-.39 to .21)</td>
<td>-.05 (-.28 to .38)</td>
<td>-.44 (-.76 to -.11)</td>
<td>-.48 (-.71 to -.25)</td>
<td>-.34 (-.47 to -.22)</td>
<td>32.6%</td>
</tr>
<tr>
<td>Passive control comparison</td>
<td>19</td>
<td>-.07 (-.29 to .15)</td>
<td>-.11 (-.39 to .17)</td>
<td>-.04 (-.36 to .29)</td>
<td>-.43 (-.74 to -.12)</td>
<td>-.39 (-.62 to -.16)</td>
<td>-.32 (-.46 to -.18)</td>
<td>46.9%</td>
</tr>
</tbody>
</table>
## eAppendix 1. Search strategy

### PubMed

<table>
<thead>
<tr>
<th>Search</th>
<th>Query</th>
</tr>
</thead>
<tbody>
<tr>
<td>#1</td>
<td>Bupropion[MeSH Terms] OR bupropion[Title/Abstract] OR 34911-55-2[EC/RN Number]</td>
</tr>
<tr>
<td>#2</td>
<td>Citalopram[MeSH Terms] OR citalopram[Title/Abstract] OR 59729-33-8[EC/RN Number]</td>
</tr>
<tr>
<td>#3</td>
<td>escitalopram[Title/Abstract] OR 128196-01-0[EC/RN Number]</td>
</tr>
<tr>
<td>#4</td>
<td>desvenlafaxine[Title/Abstract] OR 386750-22-7[EC/RN Number]</td>
</tr>
<tr>
<td>#5</td>
<td>Fluoxetine[MeSH Terms] OR fluoxetine[Title/Abstract] OR 54910-89-3[EC/RN Number]</td>
</tr>
<tr>
<td>#6</td>
<td>Fluvoxamine[MeSH Terms] OR fluvoxamine[Title/Abstract] OR 54739-18-3[EC/RN Number]</td>
</tr>
<tr>
<td>#7</td>
<td>Milnacipran[Supplementary Concept] OR levomilnacipran[Title/Abstract]</td>
</tr>
<tr>
<td>#8</td>
<td>Mirtazapine[Supplementary Concept] OR mirtazapine[Title/Abstract] OR 4685R51V7M[EC/RN Number]</td>
</tr>
<tr>
<td>#9</td>
<td>Nefazodone[Supplementary Concept] OR nefazodone[Title/Abstract]</td>
</tr>
<tr>
<td>#10</td>
<td>Paroxetine[MeSH Terms] OR paroxetine[Title/Abstract] OR 61869-08-7[EC/RN Number]</td>
</tr>
<tr>
<td>#11</td>
<td>Sertraline[MeSH Terms] OR sertraline[Title/Abstract] OR 79617-96-2[EC/RN Number]</td>
</tr>
<tr>
<td>#12</td>
<td>Trazodone[MeSH Terms] OR trazodone[Title/Abstract] OR 19794-93-5[EC/RN Number]</td>
</tr>
<tr>
<td>#13</td>
<td>Venlafaxine[Title/Abstract] OR 99300-78-4[EC/RN Number]</td>
</tr>
<tr>
<td>#14</td>
<td>Vilazodone[Title/Abstract] OR 163521-08-2[EC/RN Number]</td>
</tr>
<tr>
<td>#15</td>
<td>Vortioxetine[Supplementary Concept] OR vortioxetine[Title/Abstract] OR TKS641KOAY[EC/RN Number]</td>
</tr>
<tr>
<td>#16</td>
<td>Duloxetine[Title/Abstract] OR 116539-58-3[EC/RN Number]</td>
</tr>
<tr>
<td>#18</td>
<td>#1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14 OR #15 OR #16 OR #17</td>
</tr>
<tr>
<td>#19</td>
<td>Depression, unipolar[MeSH Terms] OR Depressive disorders[MeSH Terms] OR depress*[Title/Abstract]</td>
</tr>
<tr>
<td>#20</td>
<td>Randomized controlled trial[MeSH Terms] OR Random allocation[MeSH Terms] OR (random*[Title/Abstract] AND (control*[Title/Abstract] OR placebo*[Title/Abstract]))</td>
</tr>
<tr>
<td>#21</td>
<td>#18 AND #19 AND #20</td>
</tr>
<tr>
<td>#23</td>
<td>#19 AND #20 AND #22</td>
</tr>
<tr>
<td>#24</td>
<td>Adults[MeSH Terms] OR adult*[Title/Abstract]</td>
</tr>
<tr>
<td>#25</td>
<td>#21 AND #24</td>
</tr>
<tr>
<td>#26</td>
<td>#23 AND #24</td>
</tr>
<tr>
<td>#27</td>
<td>#25 OR #26</td>
</tr>
<tr>
<td>#28</td>
<td>Filters: Chinese, English, Italian, from 1990 - 3000/12/12</td>
</tr>
</tbody>
</table>

### PsycInfo

<table>
<thead>
<tr>
<th>Search</th>
<th>Query</th>
</tr>
</thead>
<tbody>
<tr>
<td>S1</td>
<td>SU(bupropion) OR AB(bupropion) OR T(bupropion)</td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td>---</td>
<td>---</td>
</tr>
<tr>
<td>S2</td>
<td>SU(citalopram) OR AB(citalopram) OR TI(citalopram)</td>
</tr>
<tr>
<td>S3</td>
<td>SU(escitalopram) OR AB(escitalopram) OR TI(escitalopram)</td>
</tr>
<tr>
<td>S4</td>
<td>SU(Desvenlafaxine) OR AB(Desvenlafaxine) OR TI(Desvenlafaxine)</td>
</tr>
<tr>
<td>S5</td>
<td>SU(Fluoxetine) OR AB(Fluoxetine) OR TI(Fluoxetine)</td>
</tr>
<tr>
<td>S6</td>
<td>SU(Fluvoxamine) OR AB(Fluvoxamine) OR TI(Fluvoxamine)</td>
</tr>
<tr>
<td>S7</td>
<td>SU(Levomilnacipran) OR AB(Levomilnacipran) OR TI(Levomilnacipran)</td>
</tr>
<tr>
<td>S8</td>
<td>SU(Mirtazapine) OR AB(Mirtazapine) OR TI(Mirtazapine)</td>
</tr>
<tr>
<td>S9</td>
<td>SU(Nefazodone) OR AB(Nefazodone) OR TI(Nefazodone)</td>
</tr>
<tr>
<td>S10</td>
<td>SU(Paroxetine) OR AB(Paroxetine) OR TI(Paroxetine)</td>
</tr>
<tr>
<td>S11</td>
<td>SU(Sertraline) OR AB(Sertraline) OR TI(Sertraline)</td>
</tr>
<tr>
<td>S12</td>
<td>SU(Trazodone) OR AB(Trazodone) OR TI(Trazodone)</td>
</tr>
<tr>
<td>S13</td>
<td>SU(Venlafaxine) OR AB(Venlafaxine) OR TI(Venlafaxine)</td>
</tr>
<tr>
<td>S14</td>
<td>SU(Vilazodone) OR AB(Vilazodone) OR TI(Vilazodone)</td>
</tr>
<tr>
<td>S15</td>
<td>SU(Vortioxetine) OR AB(Vortioxetine) OR TI(Vortioxetine)</td>
</tr>
<tr>
<td>S16</td>
<td>SU(Duloxetine) OR AB(Duloxetine) OR TI(Duloxetine)</td>
</tr>
<tr>
<td>S17</td>
<td>SU(Antidepressive Drugs, Second-Generation) OR TI(antidepress*) OR AB(antidepress*)</td>
</tr>
<tr>
<td>S18</td>
<td>S1 OR S2 OR S3 OR S4 OR S5 OR S6 OR S7 OR S8 OR S9 OR S10 OR S11 OR S12 OR S13 OR S14 OR S15 OR S16</td>
</tr>
<tr>
<td>S19</td>
<td>S18 AND S19 AND S20</td>
</tr>
<tr>
<td>S20</td>
<td>S19 AND S20 AND S21 AND S22</td>
</tr>
<tr>
<td>S21</td>
<td>S18 AND S19 AND S20</td>
</tr>
<tr>
<td>S22</td>
<td>S18 AND S19 AND S20</td>
</tr>
<tr>
<td>S23</td>
<td>S18 AND S19 AND S20</td>
</tr>
<tr>
<td>S24</td>
<td>S18 AND S19 AND S20</td>
</tr>
<tr>
<td>S25</td>
<td>S18 AND S19 AND S20</td>
</tr>
<tr>
<td>S26</td>
<td>S18 AND S19 AND S20</td>
</tr>
<tr>
<td>S27</td>
<td>S18 AND S19 AND S20</td>
</tr>
<tr>
<td>S28</td>
<td>S18 AND S19 AND S20</td>
</tr>
<tr>
<td></td>
<td>#27 Limit date range 1990-2021 AND Limit language: English, Chinese, Italian</td>
</tr>
</tbody>
</table>

### Cochrane Library

<table>
<thead>
<tr>
<th>ID</th>
<th>Search</th>
</tr>
</thead>
<tbody>
<tr>
<td>#1</td>
<td>bupropion:ti,ab,kw OR [mh bupropion]</td>
</tr>
<tr>
<td>#2</td>
<td>citalopram:ti,ab,kw OR [mh citalopram]</td>
</tr>
<tr>
<td>#3</td>
<td>escitalopram:ti,ab,kw OR [mh escitalopram]</td>
</tr>
<tr>
<td>#4</td>
<td>desvenlafaxine:ti,ab,kw OR [mh desvenlafaxine]</td>
</tr>
<tr>
<td>#5</td>
<td>duloxetine:ti,ab,kw OR [mh duloxetine]</td>
</tr>
<tr>
<td>#6</td>
<td>fluvoxamine:ti,ab,kw OR [mh fluvoxamine]</td>
</tr>
<tr>
<td>#7</td>
<td>fluvoxamine:ti,ab,kw OR [mh fluvoxamine]</td>
</tr>
<tr>
<td>#8</td>
<td>Levomilnacipran:ti,ab,kw OR [mh levomilnacipran]</td>
</tr>
<tr>
<td>#9</td>
<td>mirtazapine:ti,ab,kw OR [mh mirtazapine]</td>
</tr>
<tr>
<td>#10</td>
<td>nefazodone:ti,ab,kw OR [mh nefazodone]</td>
</tr>
<tr>
<td>#11</td>
<td>Paroxetine:ti,ab,kw OR [mh paroxetine]</td>
</tr>
<tr>
<td>#12</td>
<td>sertraline:ti,ab,kw OR [mh sertraline]</td>
</tr>
<tr>
<td>#13</td>
<td>Trazodone:ti,ab,kw OR [mh trazodone]</td>
</tr>
<tr>
<td>#14</td>
<td>venlafaxine:ti,ab OR [mh venlafaxine]</td>
</tr>
<tr>
<td>#15</td>
<td>vilazodone:ti,ab,kw OR [mh vilazodone]</td>
</tr>
<tr>
<td>#16</td>
<td>vortioxetine:ti,ab,kw OR [mh duloxetine]</td>
</tr>
</tbody>
</table>
#17 [mh Antidepressive Agents, Second-Generation] OR antidepress*:ti,ab,kw
#18 #1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR 11 OR 12 OR #13 OR #14 OR #15 OR #16 OR #17
#19 [mh Depression] OR [mh Depressive Disorder, Major] OR depress*:ti,ab,kw
#20 [mh Randomized Controlled Trials as Topic] OR [mh Random Controlled Trial] OR [mh Random Allocation] OR ("randomized controlled");ti,ab,kw OR ("controlled clinical");ti,ab,kw
#21 #18 AND #19 AND #20
#22 [mh Adults] OR adults:ti,ab,kw
#23 #21 AND #22
#24 [mh Exercise] OR [mh "physical activity"] OR exercise:ti,ab,kw OR training:ti,ab,kw OR lift*:ti,ab,kw OR aerobic:ti,ab,kw OR running:ti,ab,kw OR walk*:ti,ab,kw OR jogging:ti,ab,kw OR swim*:ti,ab,kw OR cycl*:ti,ab,kw
#25 #19 AND #20 AND #24
#26 #25 AND #22
#27 #23 OR #26 with Publication Year from 1990 to 2021 AND language: English, Chinese, Italian

**Embase**

<table>
<thead>
<tr>
<th>#</th>
<th>Searches</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>exp bupropion/ or bupropion.tn,ab,ti. or 34911 55 2.rn.</td>
</tr>
<tr>
<td>2</td>
<td>exp citalopram/ or citalopram.tn,ab,ti. or 59729 53 31.rn.</td>
</tr>
<tr>
<td>3</td>
<td>exp escitalopram/ or escitalopram.tn,ab,ti. or 128196 01 0.rn.</td>
</tr>
<tr>
<td>4</td>
<td>exp desvenlafaxine/ or desvenlafaxine.tn,ab,ti. or 93413 62 8.rn.</td>
</tr>
<tr>
<td>5</td>
<td>exp fluoxetine/ or fluoxetine.tn,ab,ti. or 54910 89 3.rn.</td>
</tr>
<tr>
<td>6</td>
<td>exp fluvoxamine/ or fluvoxamine.tn,ab,ti. or 54739 18 3.rn.</td>
</tr>
<tr>
<td>7</td>
<td>exp milnacipran/ or levomilnacipran.tn,ab,ti. or 96847 54 0.rn.</td>
</tr>
<tr>
<td>8</td>
<td>exp mirtazapine/ or mirtazapine.tn,ab,ti. or 85650 52 8.rn.</td>
</tr>
<tr>
<td>9</td>
<td>exp nefazodone/ or nefazodone.tn,ab,ti. or 62752 99 6.rn.</td>
</tr>
<tr>
<td>10</td>
<td>exp paroxetine/ or paroxetine.tn,ab,ti. or 61869 08 7.rn.</td>
</tr>
<tr>
<td>11</td>
<td>exp sertraline/ or sertraline.tn,ab,ti. or 79617 96 2.rn.</td>
</tr>
<tr>
<td>12</td>
<td>exp trazodone/ or trazodone.tn,ab,ti. or 19794 93 5.rn.</td>
</tr>
<tr>
<td>13</td>
<td>exp venlafaxine/ or venlafaxine.tn,ab,ti. or 93413 69 5.rn.</td>
</tr>
<tr>
<td>14</td>
<td>exp vilazodone/ or vilazodone.tn,ab,ti. or 163521 12 8.rn.</td>
</tr>
<tr>
<td>15</td>
<td>exp vortioxetine/ or vortioxetine.tn,ab,ti. or 508233 74 7.rn.</td>
</tr>
<tr>
<td>16</td>
<td>exp duloxetine/ or duloxetine.tn,ab,ti. or 116539 59 4.rn.</td>
</tr>
<tr>
<td>17</td>
<td>exp antidepressant agent/ or antidepress*:ti,ab.</td>
</tr>
<tr>
<td>18</td>
<td>1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17</td>
</tr>
<tr>
<td>19</td>
<td>exp depression/ or exp major depression/ or depress*:ti,ab,kw.</td>
</tr>
<tr>
<td>20</td>
<td>exp randomized controlled trial/ or randomized controlled trial.ti,ab,pt. or randomized placebo trial.ti,ab. or exp randomization/</td>
</tr>
<tr>
<td>21</td>
<td>18 and 19 and 20</td>
</tr>
<tr>
<td>22</td>
<td>exp exercise/ or exercise.ti,ab. or aerobic.ti,ab. or training.ti,ab. or lift*:ti,ab. or running.ti,ab. or jogging.ti,ab. or walk*:ti,ab. or swim*:ti,ab. or cycl*:ti,ab.</td>
</tr>
<tr>
<td>23</td>
<td>19 and 20 and 22</td>
</tr>
<tr>
<td>24</td>
<td>exp adults/ or adult*:ti,ab.</td>
</tr>
<tr>
<td>25</td>
<td>24 and 24</td>
</tr>
<tr>
<td>26</td>
<td>25 and 24</td>
</tr>
<tr>
<td>27</td>
<td>25 or 26</td>
</tr>
<tr>
<td>28</td>
<td>Limit 27 to yr=1990-Current, English, Chinese, Italian language</td>
</tr>
</tbody>
</table>

**Scopus**

<table>
<thead>
<tr>
<th>#</th>
<th>Query</th>
</tr>
</thead>
<tbody>
<tr>
<td>#1</td>
<td>TITLE-ABS-KEY(bupropion OR citalopram OR escitalopram OR desvenlafaxine OR fluoxetine OR fluvoxamine OR milnacipran OR mirtazapine OR nefazodone OR</td>
</tr>
</tbody>
</table>
paroxetine OR sertraline OR trazodone OR venlafaxine OR vilazodone OR vortioxetine OR duloxetine OR antidepress*)

#2 TITLE-ABS-KEY(depress*)
#3 TITLE-ABS-KEY(randomized controlled trial)
#4 TITLE-ABS-KEY(adult*)
#5 #1 AND #2 AND #3 AND #4
#6 TITLE-ABS-KEY(exercise OR 'physical activity' OR aerobic OR training OR lift* OR running OR walk* OR jogging OR swim* OR cycl*)
#7 #2 AND #3 AND #4 AND #6
#8 #5 OR #7

**SportDiscus**

<table>
<thead>
<tr>
<th>Search</th>
<th>Query</th>
</tr>
</thead>
<tbody>
<tr>
<td>S1</td>
<td>(TI(bupropion OR citalopram OR escitalopram OR desvenlafaxine OR fluoxetine OR fluvoxamine OR milnacipran OR mirtazapine OR nefazodone OR paroxetine OR sertraline OR trazodone OR venlafaxine OR vilazodone OR vortioxetine OR duloxetine OR antidepress*)) OR (AB(bupropion OR citalopram OR escitalopram OR desvenlafaxine OR fluoxetine OR fluvoxamine OR milnacipran OR mirtazapine OR nefazodone OR paroxetine OR sertraline OR trazodone OR venlafaxine OR vilazodone OR vortioxetine OR duloxetine OR antidepress*)) OR (SU(bupropion OR citalopram OR escitalopram OR desvenlafaxine OR fluoxetine OR fluvoxamine OR milnacipran OR mirtazapine OR nefazodone OR paroxetine OR sertraline OR trazodone OR venlafaxine OR vilazodone OR vortioxetine OR duloxetine OR antidepress*))</td>
</tr>
<tr>
<td>S2</td>
<td>SU(depression or depressive disorder or depressive symptoms or major depressive disorder) OR TI depress*</td>
</tr>
<tr>
<td>S3</td>
<td>SU(randomized controlled trials or rtc or randomised control trials) OR TI(random* AND control*) OR AB (random* AND control*)</td>
</tr>
<tr>
<td>S4</td>
<td>SU(adults or adult) OR TI adult* OR AB adult*</td>
</tr>
<tr>
<td>S5</td>
<td>S1 AND S2 AND S3 AND S4</td>
</tr>
<tr>
<td>S6</td>
<td>SU(exercise or physical activity) OR TI(exercise OR 'physical activity' OR aerobic OR training OR lift* OR running OR walk* OR jogging OR swim* OR cycl*) OR AB(exercise OR 'physical activity' OR aerobic OR training OR lift* OR running OR walk* OR jogging OR swim* OR cycl*)</td>
</tr>
<tr>
<td>S7</td>
<td>S2 AND S3 AND S4 AND S6</td>
</tr>
<tr>
<td>S8</td>
<td>S5 OR S7</td>
</tr>
</tbody>
</table>

**Web of Science**

<table>
<thead>
<tr>
<th>#</th>
<th>Query</th>
</tr>
</thead>
<tbody>
<tr>
<td>#1</td>
<td>TS=(bupropion OR citalopram OR escitalopram OR desvenlafaxine OR fluoxetine OR fluvoxamine OR milnacipran OR mirtazapine OR nefazodone OR paroxetine OR sertraline OR trazodone OR venlafaxine OR vilazodone OR vortioxetine OR duloxetine OR antidepress*)</td>
</tr>
<tr>
<td>#2</td>
<td>TS=(depress*)</td>
</tr>
<tr>
<td>#3</td>
<td>TS=(random* AND (control* OR placebo))</td>
</tr>
<tr>
<td>#4</td>
<td>TS=(adult*)</td>
</tr>
<tr>
<td>#5</td>
<td>TS=(exercise OR 'physical activity' OR aerobic OR training OR lift* OR running OR walk* OR jogging OR swim* OR cycl*)</td>
</tr>
<tr>
<td>#6</td>
<td>#1 AND #2 AND #3 AND #4</td>
</tr>
<tr>
<td>#7</td>
<td>#2 AND #3 AND #4 AND #5</td>
</tr>
<tr>
<td>#8</td>
<td>#6 OR #7</td>
</tr>
</tbody>
</table>
eAppendix 2. Additional methodology information

Risk of bias

The Cochrane risk of bias assessment tool (RoB-2) was used to determine the quality of the individual studies. Bias was assessed in the following domains: 1) randomization process, 2) deviations from the intended interventions, 3) missing outcome data, 4) measurement of the outcome, and 5) selection of the reported results. Each domain was assessed as having either low risk of bias, some concerns, or high risk of bias.

To implement RoB-2, we utilized the Excel template provided in the “Cochrane Handbook for Systematic Reviews of Interventions”, which includes “signalling questions” that can be used to assess bias in each domain. Each domain is automatically evaluated by an algorithm based on the signalling questions, as well as subjectively by the author. To avoid the influence of personal bias, the assessment of each domain was strictly based on the output of the algorithm.

1. Bias due to the randomization process was rated “low” if the study allocation sequence was reported as random and there was evidence that the allocation sequence was concealed. Allocation concealment was considered adequate if the allocation was carried out by investigators that were external to the project, or if authors used a form of remote or centrally administered method that ensured allocation concealment (e.g., sealed opaque envelopes). If the strategy for allocation concealment was not clearly reported, the domain was rated as having “some concerns”. If both categories were deemed to be inadequately described, the domain was rated “high”.

2. Bias due to deviations from the intended interventions was based on whether participants and/or study personnel were blinded to participants’ assigned intervention, whether there were deviations from the intervention due to the trial context, and whether an appropriate analysis was used to estimate the effect of the intervention. Bias was rated “low” if all categories were rated as low. Following the Cochrane algorithm, if participants or study personnel were aware of participants’ allocated intervention but all other categories were considered as low, the domain was still rated as “low”. If there were deviations from the interventions that were suspected to affect the outcome, and if these were not balanced between groups, or if an inappropriate statistical analysis was used that was suspected to substantially impact the outcome, the domain was rated “high”. Any other combination was rated as having “some concerns”.

3. Bias due to missing outcome data was rated “low” if data were available for all, or nearly all, participants randomized. If there was the possibility that missingness in the outcome was influenced by its true value, the domain was rated “some concerns”. If missingness in the outcome was likely influenced by its true value, the domain was rated “high”.

4. Bias in measurement of the outcome was rated “high” if the method for measuring the outcome was inappropriate, if it differed between groups, or if it was likely that the assessment was influenced by knowledge of the intervention. It was rated “some concerns” if outcome assessors were aware of the intervention received by participants, but it was not likely that assignment was influenced by knowledge of the intervention. Bias in measurement of the outcome was rated “low” if all categories were considered as low.

5. Bias in selection of the reported result was rated “low” if it was unlikely that the results were selected from multiple measurements or analyses, and data were analysed in accordance with a pre-specified plan. If no pre-specified plan was available but it was unlikely that results were selected from multiple measurements or analyses, the domain was rated “some concerns”. If it was suspected that results were selected from multiple measurements or analyses, the domain was rated “high”.

Overall risk of bias was rated “low” if all domains were rated “low”, it was rated “some concerns” if the study was judged to raise some concerns in at least one domain, but not to be at high risk of bias for any domain, and it was was rated “high” if at least one domain was considered as “high”.

**Confidence of Network Meta-analysis (CINeMA) rating**

We used the CINeMA framework to assess the overall credibility of the results. CINeMA is based on the following domains: 1) within-study bias, 2) reporting bias, 3) indirectness, 4) imprecision, 5) heterogeneity, and 6) incoherence. Within-study bias was evaluated using the RoB-2 tool. Reporting bias for each comparison was coded as “suspected” or “undetected” based on the completeness of the research and availability of published data. Indirectness was assessed as described below. To assess imprecision, heterogeneity, and incoherence, we set the clinically significant effect size to 0.35.

**Indirectness**

Indirectness was assessed based on recommended guidelines. We evaluated whether studies differed in relation to 1) population, 2) intervention, 3) outcome, and 4) whether a study showed direct evidence for at least one comparison of interest. Study indirectness was coded as “low” if three or more outcomes were considered to be “low” and no more than one was “unclear”, and coded as “high” if two or more outcomes were considered to be “high”, whereas any other combination was coded as “moderate”.

eAppendix 3. Pairwise meta-analyses

Comparative effectiveness on depressive symptoms from pairwise meta-analyses

<table>
<thead>
<tr>
<th>Study</th>
<th>Exercise Total Mean (SD)</th>
<th>Antidepressants Total Mean (SD)</th>
<th>Standardised Mean Difference (SMD)</th>
<th>95%-CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bluemethal(2007)</td>
<td>51 9.20 (6.6025)</td>
<td>49 10.20 (6.0380)</td>
<td>-0.15 (-0.54, 0.24)</td>
<td></td>
</tr>
<tr>
<td>Higashi(2011)</td>
<td>170 5.35 (5.1300)</td>
<td>171 5.85 (5.4500)</td>
<td>-0.10 (-0.31, 0.11)</td>
<td></td>
</tr>
<tr>
<td>Bluemethal(1999)</td>
<td>53 8.10 (6.5419)</td>
<td>48 7.80 (5.5918)</td>
<td>0.05 (0.04, 0.44)</td>
<td></td>
</tr>
</tbody>
</table>

Random effects model 280 268
Heterogeneity: τ² = 0.07, p = 0.0075

<table>
<thead>
<tr>
<th>Study</th>
<th>Exercise Total Mean (SD)</th>
<th>Control Total Mean (SD)</th>
<th>Standardised Mean Difference (SMD)</th>
<th>95%-CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dam(2003)</td>
<td>17 9.00 (3.0000)</td>
<td>13 14.00 (4.9000)</td>
<td>-1.16 (-1.94, -0.37)</td>
<td></td>
</tr>
<tr>
<td>McShee(1991)</td>
<td>10 11.10 (3.0000)</td>
<td>10 14.70 (3.0000)</td>
<td>-1.62 (-1.97, -0.68)</td>
<td></td>
</tr>
<tr>
<td>Horan(2012)</td>
<td>10 16.00 (6.0000)</td>
<td>10 22.80 (4.9000)</td>
<td>-0.99 (-1.90, 0.05)</td>
<td></td>
</tr>
<tr>
<td>Scalet(2010)</td>
<td>10 13.31 (5.0000)</td>
<td>14 16.25 (6.4600)</td>
<td>-0.05 (-1.05, 0.89)</td>
<td></td>
</tr>
<tr>
<td>Bluemethal(2007)</td>
<td>51 9.20 (6.6258)</td>
<td>49 11.00 (6.7180)</td>
<td>-0.27 (-0.95, 0.31)</td>
<td></td>
</tr>
<tr>
<td>Knight(2012)</td>
<td>54 11.30 (6.0000)</td>
<td>55 10.50 (6.4000)</td>
<td>0.12 (0.28, 0.49)</td>
<td></td>
</tr>
</tbody>
</table>

Random effects model 160 165
Heterogeneity: τ² = 0.03, p = 0.01

<table>
<thead>
<tr>
<th>Study</th>
<th>Antidepressants Total Mean (SD)</th>
<th>Control Total Mean (SD)</th>
<th>Standardised Mean Difference (SMD)</th>
<th>95%-CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Moran(2006)</td>
<td>20 6.70 (3.9915)</td>
<td>20 10.60 (5.0154)</td>
<td>-0.88 (-1.46, -0.30)</td>
<td></td>
</tr>
<tr>
<td>Deleuc(2004)</td>
<td>93 8.10 (5.7500)</td>
<td>93 11.10 (6.3009)</td>
<td>-0.53 (-1.02, -0.23)</td>
<td></td>
</tr>
<tr>
<td>Caddick(2004)</td>
<td>95 9.30 (5.7500)</td>
<td>89 12.20 (6.3008)</td>
<td>-0.51 (-1.01, -0.21)</td>
<td></td>
</tr>
<tr>
<td>Phipps(1996)</td>
<td>105 8.00 (5.7500)</td>
<td>96 10.60 (6.3008)</td>
<td>-0.46 (-0.95, 0.03)</td>
<td></td>
</tr>
<tr>
<td>Gomp(2006)</td>
<td>127 10.30 (6.4000)</td>
<td>130 13.00 (6.9000)</td>
<td>-0.40 (-0.95, 0.15)</td>
<td></td>
</tr>
<tr>
<td>Deleuc(2003)</td>
<td>129 9.50 (5.7500)</td>
<td>139 12.90 (6.3008)</td>
<td>-0.48 (-0.95, 0.09)</td>
<td></td>
</tr>
<tr>
<td>Ma(2015)</td>
<td>19 7.00 (2.6820)</td>
<td>18 8.80 (3.0065)</td>
<td>-0.24 (-0.67, 0.19)</td>
<td></td>
</tr>
<tr>
<td>Perri(2006)</td>
<td>102 9.10 (5.7500)</td>
<td>96 9.90 (5.0508)</td>
<td>-0.14 (-0.42, 0.14)</td>
<td></td>
</tr>
<tr>
<td>Bluemethal(2007)</td>
<td>49 10.20 (6.6258)</td>
<td>49 11.90 (6.7180)</td>
<td>-0.12 (-0.62, 0.38)</td>
<td></td>
</tr>
<tr>
<td>Bjorklund(2005)</td>
<td>54 14.00 (6.4000)</td>
<td>55 15.50 (6.7000)</td>
<td>-0.08 (-0.45, 0.29)</td>
<td></td>
</tr>
<tr>
<td>Faze(2005)</td>
<td>47 13.30 (7.3000)</td>
<td>43 12.00 (6.4000)</td>
<td>0.10 (0.31, 0.51)</td>
<td></td>
</tr>
</tbody>
</table>

Random effects model 830 787
Heterogeneity: τ² = 0.04, p = 0.0002

<table>
<thead>
<tr>
<th>Study</th>
<th>Combination Total Mean (SD)</th>
<th>Antidepressants Total Mean (SD)</th>
<th>Standardised Mean Difference (SMD)</th>
<th>95%-CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dam(2014)</td>
<td>22 14.00 (8.4177)</td>
<td>20 18.50 (8.4200)</td>
<td>-0.52 (-1.14, 0.09)</td>
<td></td>
</tr>
<tr>
<td>Squares(2010)</td>
<td>29 11.38 (5.9400)</td>
<td>26 12.64 (5.7400)</td>
<td>-0.25 (-0.72, 0.27)</td>
<td></td>
</tr>
<tr>
<td>Mather(2012)</td>
<td>43 12.00 (6.5054)</td>
<td>43 13.70 (6.5005)</td>
<td>-0.17 (-0.59, 0.24)</td>
<td></td>
</tr>
<tr>
<td>Bluemethal(1999)</td>
<td>55 9.30 (7.0342)</td>
<td>48 7.80 (5.5916)</td>
<td>0.23 (0.16, 0.30)</td>
<td></td>
</tr>
</tbody>
</table>

Random effects model 149 139
Heterogeneity: τ² = 0.41, p = 0.0004

<table>
<thead>
<tr>
<th>Study</th>
<th>Combination Total Mean (SD)</th>
<th>Exercise Total Mean (SD)</th>
<th>Standardised Mean Difference (SMD)</th>
<th>95%-CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bluemethal(1999)</td>
<td>55 9.30 (7.0342)</td>
<td>53 10.10 (6.5419)</td>
<td>0.18 (0.2, 0.55)</td>
<td></td>
</tr>
</tbody>
</table>

19
### Comparative effectiveness on acceptability from pairwise meta-analyses

<table>
<thead>
<tr>
<th>Study</th>
<th>EX Events</th>
<th>Total</th>
<th>AD Events</th>
<th>Total</th>
<th>Risk Ratio</th>
<th>RR 95%-CI</th>
<th>Heterogeneity: $I^2 = 0%$, $Q^2 = 0.0001$, $p = 0.81$</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hidalgo(2021)</td>
<td>110</td>
<td>175</td>
<td>78</td>
<td>171</td>
<td>1.37</td>
<td>[1.12; 1.67]</td>
<td></td>
</tr>
<tr>
<td>Blumenthal(2007)</td>
<td>10</td>
<td>51</td>
<td>7</td>
<td>49</td>
<td>1.27</td>
<td>[0.57; 3.32]</td>
<td></td>
</tr>
<tr>
<td>Blumenthal(1999)</td>
<td>14</td>
<td>53</td>
<td>7</td>
<td>48</td>
<td>1.61</td>
<td>[0.80; 4.11]</td>
<td></td>
</tr>
<tr>
<td><strong>Random effects model</strong></td>
<td><strong>280</strong></td>
<td><strong>268</strong></td>
<td><strong>1.40</strong></td>
<td><strong>[1.12; 1.72]</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Study</th>
<th>EX Events</th>
<th>Total</th>
<th>CT Events</th>
<th>Total</th>
<th>Risk Ratio</th>
<th>RR 95%-CI</th>
<th>Heterogeneity: $I^2 = 14%$, $Q^2 = 0.1044$, $p = 0.31$</th>
</tr>
</thead>
<tbody>
<tr>
<td>Donn(2005)</td>
<td>7</td>
<td>17</td>
<td>8</td>
<td>13</td>
<td>0.67</td>
<td>[0.33; 1.38]</td>
<td></td>
</tr>
<tr>
<td>Blumenthal(2007)</td>
<td>10</td>
<td>51</td>
<td>14</td>
<td>49</td>
<td>0.93</td>
<td>[0.34; 1.40]</td>
<td></td>
</tr>
<tr>
<td>Knight(2012)</td>
<td>9</td>
<td>56</td>
<td>6</td>
<td>59</td>
<td>1.58</td>
<td>[0.69; 4.15]</td>
<td></td>
</tr>
<tr>
<td><strong>Random effects model</strong></td>
<td><strong>124</strong></td>
<td><strong>121</strong></td>
<td><strong>0.84</strong></td>
<td><strong>[0.27; 2.58]</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Study</th>
<th>AD Events</th>
<th>Total</th>
<th>CT Events</th>
<th>Total</th>
<th>Risk Ratio</th>
<th>RR 95%-CI</th>
<th>Heterogeneity: $I^2 = 0%$, $Q^2 = 0.0273$, $p = 0.88$</th>
</tr>
</thead>
<tbody>
<tr>
<td>Blumenthal(2007)</td>
<td>7</td>
<td>49</td>
<td>14</td>
<td>49</td>
<td>0.50</td>
<td>[0.22; 1.53]</td>
<td></td>
</tr>
<tr>
<td>Deeks(2004)</td>
<td>4</td>
<td>93</td>
<td>6</td>
<td>93</td>
<td>0.07</td>
<td>[0.01; 2.29]</td>
<td></td>
</tr>
<tr>
<td>Masl(2015)</td>
<td>4</td>
<td>20</td>
<td>7</td>
<td>20</td>
<td>0.74</td>
<td>[0.25; 2.16]</td>
<td></td>
</tr>
<tr>
<td>Moreno(2006)</td>
<td>4</td>
<td>20</td>
<td>7</td>
<td>20</td>
<td>0.74</td>
<td>[0.25; 2.16]</td>
<td></td>
</tr>
<tr>
<td>Castoldi(2008)</td>
<td>23</td>
<td>127</td>
<td>25</td>
<td>130</td>
<td>0.94</td>
<td>[0.57; 1.57]</td>
<td></td>
</tr>
<tr>
<td>Fiwa(2005)</td>
<td>23</td>
<td>47</td>
<td>22</td>
<td>43</td>
<td>0.90</td>
<td>[0.50; 1.63]</td>
<td></td>
</tr>
<tr>
<td>Goldsour(2004)</td>
<td>38</td>
<td>91</td>
<td>37</td>
<td>89</td>
<td>1.00</td>
<td>[0.71; 1.42]</td>
<td></td>
</tr>
<tr>
<td>Delee(2002)</td>
<td>50</td>
<td>128</td>
<td>49</td>
<td>139</td>
<td>1.11</td>
<td>[0.81; 1.51]</td>
<td></td>
</tr>
<tr>
<td>Birkenshch(2005)</td>
<td>20</td>
<td>57</td>
<td>16</td>
<td>58</td>
<td>1.13</td>
<td>[0.87; 1.50]</td>
<td></td>
</tr>
<tr>
<td>Philip(1999)</td>
<td>1</td>
<td>110</td>
<td>0</td>
<td>47</td>
<td>1.29</td>
<td>[0.65; 2.56]</td>
<td></td>
</tr>
<tr>
<td>Perlak(2006)</td>
<td>13</td>
<td>103</td>
<td>9</td>
<td>99</td>
<td>1.39</td>
<td>[0.62; 3.16]</td>
<td></td>
</tr>
<tr>
<td><strong>Random effects model</strong></td>
<td><strong>845</strong></td>
<td><strong>799</strong></td>
<td><strong>0.97</strong></td>
<td><strong>[0.84; 1.13]</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Study</th>
<th>Comb Events</th>
<th>Total</th>
<th>AD Events</th>
<th>Total</th>
<th>Risk Ratio</th>
<th>RR 95%-CI</th>
<th>Heterogeneity: $I^2 = 0%$, $Q^2 = 0.0357$, $p = 0.52$</th>
</tr>
</thead>
<tbody>
<tr>
<td>Darlebs(2014)</td>
<td>4</td>
<td>22</td>
<td>6</td>
<td>20</td>
<td>0.61</td>
<td>[0.20; 1.84]</td>
<td></td>
</tr>
<tr>
<td>Siquina(2016)</td>
<td>9</td>
<td>29</td>
<td>8</td>
<td>20</td>
<td>1.69</td>
<td>[0.49; 2.41]</td>
<td></td>
</tr>
<tr>
<td>Blumenthal(1999)</td>
<td>11</td>
<td>55</td>
<td>7</td>
<td>48</td>
<td>1.37</td>
<td>[0.58; 3.20]</td>
<td></td>
</tr>
<tr>
<td><strong>Random effects model</strong></td>
<td><strong>106</strong></td>
<td><strong>96</strong></td>
<td><strong>1.63</strong></td>
<td><strong>[0.40; 2.68]</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Study</th>
<th>Comb Events</th>
<th>Total</th>
<th>EX Events</th>
<th>Total</th>
<th>Risk Ratio</th>
<th>RR 95%-CI</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Blumenthal(1999)</td>
<td>11</td>
<td>55</td>
<td>14</td>
<td>53</td>
<td>0.76</td>
<td>[0.36; 1.52]</td>
<td></td>
</tr>
</tbody>
</table>

eAppendix 4. References


